
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3EAuthor Manuscript%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Prevalence and Outcomes of p.Val142Ile Transthyretin Amyloidosis Cardiomyopathy: A Systematic Review - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="DB2B0DA3925FD0033C0DA3001106D52A.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="nihpa">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="manuscript">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8530896/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Circulation. Genomic and precision medicine">
<meta name="citation_title" content="Prevalence and Outcomes of p.Val142Ile Transthyretin Amyloidosis Cardiomyopathy: A Systematic Review">
<meta name="citation_author" content="Pranav Chandrashekar">
<meta name="citation_author_institution" content="Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR">
<meta name="citation_author" content="Laith Alhuneafat">
<meta name="citation_author_institution" content="Department of Medicine, Allegheny General Hospital, Pittsburgh, PA">
<meta name="citation_author" content="Meghan Mannello">
<meta name="citation_author_institution" content="Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR">
<meta name="citation_author" content="Lana Al-Rashdan">
<meta name="citation_author_institution" content="Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR">
<meta name="citation_author" content="Morris M Kim">
<meta name="citation_author_institution" content="Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR">
<meta name="citation_author" content="Jason Dungu">
<meta name="citation_author_institution" content="Essex Cardiothoracic Center, Essex, England, UK">
<meta name="citation_author" content="Kevin Alexander">
<meta name="citation_author_institution" content="School of Medicine, Stanford University, Palo Alto, CA">
<meta name="citation_author" content="Ahmad Masri">
<meta name="citation_author_institution" content="Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR">
<meta name="citation_publication_date" content="2021 Aug 31">
<meta name="citation_volume" content="14">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e003356">
<meta name="citation_doi" content="10.1161/CIRCGEN.121.003356">
<meta name="citation_pmid" content="34461737">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8530896/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8530896/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8530896/pdf/nihms-1731320.pdf">
<meta name="description" content="The p.Val142Ile variant, predominantly found among people of African descent, is the most common cause of variant transthyretin amyloidosis (vATTR) and carriers predominantly develop a cardiomyopathy (vATTR-CM) phenotype. Yet, there are conflicting ...">
<meta name="og:title" content="Prevalence and Outcomes of p.Val142Ile Transthyretin Amyloidosis Cardiomyopathy: A Systematic Review">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The p.Val142Ile variant, predominantly found among people of African descent, is the most common cause of variant transthyretin amyloidosis (vATTR) and carriers predominantly develop a cardiomyopathy (vATTR-CM) phenotype. Yet, there are conflicting ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC8530896/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="8530896">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1161/CIRCGEN.121.003356"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/nihms-1731320.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8530896%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/8530896/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/8530896/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8530896/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-nihpa.png" alt="NIHPA Author Manuscripts logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to NIHPA Author Manuscripts" title="Link to NIHPA Author Manuscripts" shape="default" href="https://www.hhs.gov/open/public-access-guiding-principles/index.html" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Circ Genom Precis Med</button></div>. Author manuscript; available in PMC: 2022 Oct 1.</div>
<div>
<em>Published in final edited form as: </em>Circ Genom Precis Med. 2021 Aug 31;14(5):e003356. doi: <a href="https://doi.org/10.1161/CIRCGEN.121.003356" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1161/CIRCGEN.121.003356</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Circ%20Genom%20Precis%20Med%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Circ%20Genom%20Precis%20Med%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Circ%20Genom%20Precis%20Med%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Circ%20Genom%20Precis%20Med%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Prevalence and Outcomes of p.Val142Ile Transthyretin Amyloidosis Cardiomyopathy: A Systematic Review</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chandrashekar%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Pranav Chandrashekar</span></a><div hidden="hidden" id="id1">
<h3>
<span class="name western">Pranav Chandrashekar</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>1</sup>Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chandrashekar%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Pranav Chandrashekar</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhuneafat%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Laith Alhuneafat</span></a><div hidden="hidden" id="id2">
<h3>
<span class="name western">Laith Alhuneafat</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>2</sup>Department of Medicine, Allegheny General Hospital, Pittsburgh, PA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alhuneafat%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Laith Alhuneafat</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mannello%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Meghan Mannello</span></a><div hidden="hidden" id="id3">
<h3>
<span class="name western">Meghan Mannello</span>, <span class="degrees">MS</span>
</h3>
<div class="p">
<sup>1</sup>Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mannello%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Meghan Mannello</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Al-Rashdan%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Lana Al-Rashdan</span></a><div hidden="hidden" id="id4">
<h3>
<span class="name western">Lana Al-Rashdan</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>1</sup>Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Al-Rashdan%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lana Al-Rashdan</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20MM%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Morris M Kim</span></a><div hidden="hidden" id="id5">
<h3>
<span class="name western">Morris M Kim</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>1</sup>Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20MM%22%5BAuthor%5D" class="usa-link"><span class="name western">Morris M Kim</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dungu%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Jason Dungu</span></a><div hidden="hidden" id="id6">
<h3>
<span class="name western">Jason Dungu</span>, <span class="degrees">FRCP PhD</span>
</h3>
<div class="p">
<sup>3</sup>Essex Cardiothoracic Center, Essex, England, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dungu%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jason Dungu</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alexander%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Kevin Alexander</span></a><div hidden="hidden" id="id7">
<h3>
<span class="name western">Kevin Alexander</span>, <span class="degrees">MD</span>
</h3>
<div class="p">
<sup>4</sup>School of Medicine, Stanford University, Palo Alto, CA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alexander%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kevin Alexander</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Masri%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Ahmad Masri</span></a><div hidden="hidden" id="id8">
<h3>
<span class="name western">Ahmad Masri</span>, <span class="degrees">MD, MS</span>
</h3>
<div class="p">
<sup>1</sup>Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Masri%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmad Masri</span></a>
</div>
</div>
<sup>1</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="A1">
<sup>1</sup>Amyloidosis Center, Knight Cardiovascular Institute, Portland, OR</div>
<div id="A2">
<sup>2</sup>Department of Medicine, Allegheny General Hospital, Pittsburgh, PA</div>
<div id="A3">
<sup>3</sup>Essex Cardiothoracic Center, Essex, England, UK</div>
<div id="A4">
<sup>4</sup>School of Medicine, Stanford University, Palo Alto, CA</div>
<div class="author-notes p"><div class="fn" id="CR1">
<sup>✉</sup><p class="display-inline"><strong>Correspondence:</strong> Ahmad Masri, MD MS, Assistant Professor of Medicine, Mail code: UHN-62, 3181 SW Sam Jackson Rd, Portland, OR 97239, Tel: 503-494-8582, <span>Masria@ohsu.edu</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Issue date 2021 Oct.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none"><div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div></div>
</div>
<div>PMCID: PMC8530896  NIHMSID: NIHMS1731320  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34461737/" class="usa-link">34461737</a>
</div>
<div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>The publisher's version of this article is available at <a href="https://doi.org/10.1161/CIRCGEN.121.003356" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Circ Genom Precis Med</a>
</div></div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="ABS1"><h2>Abstract</h2>
<section id="S1"><h3 class="pmc_sec_title">Background:</h3>
<p id="P1">The p.Val142Ile variant, predominantly found among people of African descent, is the most common cause of variant transthyretin amyloidosis (vATTR) and carriers predominantly develop a cardiomyopathy (vATTR-CM) phenotype. Yet, there are conflicting data on the prevalence and outcomes of p.Val142Ile variant carriers.</p></section><section id="S2"><h3 class="pmc_sec_title">Methods:</h3>
<p id="P2">We performed a systematic review of the prevalence and outcomes of p.Val142Ile vATTR-CM among subjects of African descent. We found 62 relevant articles after searching the MEDLINE databases from 1980 – 2020 that reported data for approximately 150,000 subjects.</p></section><section id="S3"><h3 class="pmc_sec_title">Results:</h3>
<p id="P3">The reported worldwide prevalence of the p.Val142Ile variant is 0.3% – 1.6% in the general population. Among people of African descent, the reported prevalence from all studies ranges from 1.1% to 9.8%, but for studies with &gt;1000 subjects it is 3% −3.5%. The prevalence of the p.Val142Ile variant in a region is dependent on the reported percentage of subjects who are of African descent in that region. p.Val142Ile vATTR-CM typically presents in the 7–8<sup>th</sup> decade of life and the majority of cases reported were male, with 25% – 38% diagnosed with atrial fibrillation. It was associated with a longitudinally worse quality of life and a lower adjusted survival compared to other types of ATTR-CM.</p></section><section id="S4"><h3 class="pmc_sec_title">Conclusion:</h3>
<p id="P4">The p.Val142Ile variant is the most common variant of the transthyretin gene with most carriers being of African descent. The true penetrance is unknown but the p.Val142Ile variant is associated with increased rates of incident heart failure and portends a lower overall survival. Increased awareness could lead to earlier diagnosis and improved heart failure outcomes among those of African descent, which is of increasing importance given the advent of novel therapeutics for this disease.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Genetics, Cardiomyopathy, race and ethnicity, p.Val142Ile, transthyretin, amyloidosis, African descent</p></section></section><section id="S5"><h2 class="pmc_sec_title">Introduction</h2>
<p id="P5">Variants in the transthyretin (TTR) gene which destabilize the TTR tetramer are associated with the development of hereditary or variant transthyretin amyloidosis (vATTR). Some variants are predominantly associated with a polyneuropathy phenotype, some with a cardiomyopathy phenotype (vATTR-CM), and others show a mixed phenotype. The most commonly identified variant is caused by a single amino acid substitution of valine to isoleucine at position 142 (p.Val142Ile or p.V142I or V142I), historically reported as p.Val122Ile as a 20-amino acid signal peptide at the start of the TTR gene was previously not incorporated into the codon count<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a>,<a href="#R2" class="usa-link" aria-describedby="R2">2</a></sup>. The geographic origin of this coding sequence is consistent with a founder variant in West Africa<sup><a href="#R2" class="usa-link" aria-describedby="R2">2</a></sup>. This was determined based on analysis of de-identified DNA samples from 14 modern African countries. Higher prevalence of the variant among the non-Bantu-speaking Niger-Kordofanian-derived populations suggests that the variant arose prior to the so-called Bantu expansion from 1000 B.C. to 500 A.D. This is the ancestry both commonly found in countries from where 50–70% of Africans forced into slave labor were brought to North America during the Atlantic slave trade in the 16<sup>th</sup> to 19<sup>th</sup> century and that is mostly highly represented in African Americans, which further supports the worldwide distribution of this allele. As a result of this the prevalence of p.Val142Ile carrier status has been estimated to be approximately 3–4% among the United States African American population (<a href="#F1" class="usa-link">Figure 1</a>) <sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a>,<a href="#R3" class="usa-link" aria-describedby="R3">3</a></sup>.</p>
<figure class="fig xbox font-sm" id="F1"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8530896_nihms-1731320-f0001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e90/8530896/f8082a8fa376/nihms-1731320-f0001.jpg" loading="lazy" height="520" width="800" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P62">Geographical Distribution of p.Val142Ile Variant Prevalence. World map that shows prevalence of p.Val142Ile among subjects of African descent is highest in West Africa, with next highest in USA, UK, and the Caribbean. Dark blue arrows represent 16<sup>th</sup> century Atlantic slave trade routes providing an explanation for higher rates of p.Val142Ile in these countries. || Expanded map of USA and UK showing prevalence of p.Val142Ile variant from reported studies among those of African descent and among vATTR-CM. || Inset blue box: Prevalence of p.Val142Ile variant among those of African descent is 3% – 3.5% when restricted to studies with at least 1000 subjects. When all studies are considered, the prevalence ranges from 1.1% – 9.8%. | Prevalence of p.Val142Ile variant among vATTR-CM is 66% – 79% in the USA and UK. The prevalence ranges from 0% – 22% among studies outside of the USA and UK. | Demographics of p.Val142Ile vATTR-CM have been summarized, full details are available in <a href="#T4" class="usa-link">Table 4</a>. (<em>Created with</em>
<a href="https://BioRender.com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">BioRender.com</a>)</p></figcaption></figure><p id="P6">p.Val142Ile vATTR-CM remains an underdiagnosed cause of heart failure (HF) among those of African descent<sup><a href="#R4" class="usa-link" aria-describedby="R4">4</a>,<a href="#R5" class="usa-link" aria-describedby="R5">5</a></sup>. Historically, the diagnosis required an invasive endomyocardial biopsy, and the treatment of ATTR-CM was limited to supportive care, providing little incentive to search for and diagnose these patients. The resurgence of bone scintigraphy and the increased utilization of cardiac magnetic resonance imaging has uncovered a significant prevalence of ATTR-CM<sup><a href="#R6" class="usa-link" aria-describedby="R6">6</a>–<a href="#R8" class="usa-link" aria-describedby="R8">8</a></sup>. With the advent of tafamidis, a TTR tetramer stabilizer shown to improve quality of life and decrease mortality in ATTR-CM, as well as other TTR silencing drugs that decrease the progression of polyneuropathy in vATTR, early identification of patients with ATTR has become paramount<sup><a href="#R9" class="usa-link" aria-describedby="R9">9</a>–<a href="#R12" class="usa-link" aria-describedby="R12">12</a></sup>. The purpose of this systematic review is to summarize the evidence of the prevalence of p.Val142Ile carriers and the vATTR-CM phenotype among those of African descent as well as the demographics and clinical outcomes of p.Val142Ile vATTR-CM.</p></section><section id="S6"><h2 class="pmc_sec_title">Methods</h2>
<p id="P7">The full methods are available in the <a href="#SD1" class="usa-link">Supplemental Material</a>. Briefly, we conducted this systematic review of published literature with an inclusion criteria of original studies of adults, both interventional and non-interventional, with the p.Val142Ile variant or p.Val142Ile vATTR-CM that reported p.Val142Ile prevalence, its association with HF, demographics of vATTR-CM, and clinical outcomes of p.Val142Ile vATTR-CM. We identified 62 studies that were included in this systematic review (<a href="#F2" class="usa-link">Figure 2</a>, <a href="#SD1" class="usa-link">Supplemental Table I</a>) <sup><a href="#R13" class="usa-link" aria-describedby="R13">13</a></sup>. The authors declare that all supporting data are available within the article and its <a href="#SD1" class="usa-link">online supplemental material</a>. This study was exempt from institutional review board approval.</p>
<figure class="fig xbox font-sm" id="F2"><h3 class="obj_head">Figure 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=8530896_nihms-1731320-f0002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e90/8530896/08affdc7ec6e/nihms-1731320-f0002.jpg" loading="lazy" height="962" width="800" alt="Figure 2."></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p id="P63">PRISMA flow diagram for search strategy and results.</p></figcaption></figure></section><section id="S7"><h2 class="pmc_sec_title">Results</h2>
<section id="S8"><h3 class="pmc_sec_title">Prevalence of p.Val142Ile Variant in General Population</h3>
<p id="P8">The best estimate of the p.Val142Ile variant prevalence in the general population is 0.3%, which comes from the large GnomAD Database with data from &gt;138,000 subjects compiled from multiple large-scale sequencing projects across the world (<a href="#SD1" class="usa-link">Supplemental Table II</a>)<sup><a href="#R14" class="usa-link" aria-describedby="R14">14</a>–<a href="#R16" class="usa-link" aria-describedby="R16">16</a></sup>. Based on these data, in the general population the p.Val142Ile variant is likely the most common cause of vATTR in the world, representing approximately 88% of all variants that affect function<sup><a href="#R14" class="usa-link" aria-describedby="R14">14</a></sup>. The prevalence of the p.Val142Ile variant in a region is dependent on the reported percentage of subjects who are of African descent in that region. For example, in the GnomAD Database, 8.6% were reported as African descent and the p.Val142Ile variant prevalence was 0.30%<sup><a href="#R14" class="usa-link" aria-describedby="R14">14</a></sup>. In a smaller study in Indiana among 1973 consecutive newborns, half were of African descent, and the p.Val142Ile prevalence was 1.62%<sup><a href="#R16" class="usa-link" aria-describedby="R16">16</a></sup>.</p></section><section id="S9"><h3 class="pmc_sec_title">Prevalence of p.Val142Ile Variant among those of African descent</h3>
<p id="P9">Among people of African descent in a population, the prevalence of the p.Val142Ile variant ranges from 1.1% to 9.8% and the allele frequency 0.006 to 0.058 (<a href="#T1" class="usa-link">Table 1</a>)<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a>,<a href="#R2" class="usa-link" aria-describedby="R2">2</a>,<a href="#R14" class="usa-link" aria-describedby="R14">14</a>–<a href="#R23" class="usa-link" aria-describedby="R23">23</a></sup>. This was determined by compiling data from several prospective cohort studies and genetic biobanks. When restricting to only studies with at least 1000 subjects, the prevalence ranges from 3.0% to 3.5%. There was not a large variation in the prevalence despite being from various regions in the USA, failing to reveal any obvious clustering (<a href="#F1" class="usa-link">Figure 1</a>).</p>
<section class="tw xbox font-sm" id="T1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p id="P64">Prevalence of p.Val142Ile Variant: African descent only</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="all">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead><tr>
<th align="center" valign="middle" rowspan="1" colspan="1">Data Source, Location</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Time Period</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Allele Frequency</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Prevalence of p.Val142Ile variant</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">GnomAD Database, International<sup><a href="#R14" class="usa-link" aria-describedby="R14">14</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2017–2018</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.016</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.2% (385/11,935)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">BioMe BioBank, USA<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2007–2015</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.2% (211/6609)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Penn Medicine Bio Bank, USA<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2008–2017</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.3% (190/5737)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Yale-Penn Cohort, USA<sup><a href="#R23" class="usa-link" aria-describedby="R23">23</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.018</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.5% (152/4361)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">ARIC Cohort, USA<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1987–2007</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.2% (124/3856)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Multiple databases, USA<sup><a href="#R22" class="usa-link" aria-describedby="R22">22</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1949–1991</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.020</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.9% (65/1688)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Newborn Cord Blood Marion County, Indiana<sup><a href="#R16" class="usa-link" aria-describedby="R16">16</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.015</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.0% (30/1000)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">CHS Cohort, USA<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1989–1993</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.011</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.1% (17/805)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Kaiser Health Appraisal Clinic, SD, USA<sup><a href="#R19" class="usa-link" aria-describedby="R19">19</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.015</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3.0% (16/526)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">New York University and NY Veterans Clinic, USA<sup><a href="#R21" class="usa-link" aria-describedby="R21">21</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1995–2004</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">4.9% (23/471)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Random healthy South Africa Volunteers, Africa<sup><a href="#R17" class="usa-link" aria-describedby="R17">17</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.006</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1.1% (1/89)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Indianapolis Veteran’s Administration Hospital, USA<sup><a href="#R17" class="usa-link" aria-describedby="R17">17</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.058</td>
<td align="center" valign="middle" rowspan="1" colspan="1">9.8% (5/51)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Newborns, New York, USA<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.019</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Jackson Heart Study, USA<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2000–2004</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.017</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Dallas Heart Study, USA<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">1999</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.018</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">San Diego Wellness, USA<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.021</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Southwest United States Thousand Genome, USA<sup><a href="#R1" class="usa-link" aria-describedby="R1">1</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.076</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">African DNA Samples + 1000Genomes Project, Africa<sup><a href="#R2" class="usa-link" aria-describedby="R2">2</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0.020</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"></td>
<td align="center" valign="middle" rowspan="1" colspan="1"></td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0.006 – 0.058</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>1.1% – 9.8%</strong>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="TFN1"><p id="P65">Sorted by decreasing sample size.</p></div>
<div class="fn" id="TFN2"><p id="P66">ARIC: Atherosclerosis Risk in Communities; CHS: Cardiovascular Health Study; n/r: not reported; USA: United States of America</p></div>
</div></section><p id="P10">Only two small studies were found that evaluated subjects in Africa<sup><a href="#R2" class="usa-link" aria-describedby="R2">2</a>,<a href="#R17" class="usa-link" aria-describedby="R17">17</a></sup>. In the largest one to date, Jacobson et al compiled several smaller studies in Africa and found that the allele prevalence varies from 0.0253 in high prevalence areas to 0.010 in the lowest prevalence areas<sup><a href="#R2" class="usa-link" aria-describedby="R2">2</a></sup>. Strong inferences and conclusions from such studies are limited by the lack or a large systematic evaluation of cohorts in Africa<sup><a href="#R2" class="usa-link" aria-describedby="R2">2</a>,<a href="#R17" class="usa-link" aria-describedby="R17">17</a></sup>. Analysis of the GnomAD database showed that 92.3% of all p.Val142Ile variant carriers were of African descent. Although rare, Gentile et al described a series of 12 Caucasian family members with the p.Val142Ile variant from two hospitals in Italy<sup><a href="#R24" class="usa-link" aria-describedby="R24">24</a></sup>.</p></section><section id="S10"><h3 class="pmc_sec_title">Prevalence of p.Val142Ile Variant among those with confirmed transthyretin amyloidosis phenotype</h3>
<p id="P11">There is a wide geographic variation in the distribution of the underlying genetic variant found in patients with vATTR phenotype. The prevalence of p.Val142Ile appears to be higher in the USA and UK ranging from 11% – 84% among those with a vATTR phenotype. In all these studies greater than 75% of p.Val142Ile carriers were of African descent (<a href="#SD1" class="usa-link">Supplemental Table III</a>)<sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a>–<a href="#R28" class="usa-link" aria-describedby="R28">28</a></sup>. In contrast, the best estimate of the prevalence in the rest of the world is 0.78% and this comes from the THAOS rest of world (ROW) registry. Smaller individual studies, except for one French cohort, show a similarly lower prevalence<sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a>,<a href="#R29" class="usa-link" aria-describedby="R29">29</a>–<a href="#R40" class="usa-link" aria-describedby="R40">40</a></sup>.</p>
<p id="P12">Autopsy studies show comparable results with Jacobson et al demonstrating that in Los Angeles County, USA among 45 viable myocardial blocks found to have transthyretin amyloid deposits (58% African descent), 13% were positive for the p.Val142Ile variant<sup><a href="#R3" class="usa-link" aria-describedby="R3">3</a></sup>. In Germany, Eriksson et al evaluated 30 ATTR pathology specimens (anti-ATTR immunostaining positive) from its amyloid pathology registry, a third were myocardial<sup><a href="#R41" class="usa-link" aria-describedby="R41">41</a></sup>. Among all 30, only one colon specimen was positive, showing a polymorphism for both p.Val142Ile and p.Gly26Ser.</p>
<p id="P13">Among those diagnosed with vATTR-CM phenotype in the USA and UK 66% – 79% carried the p.Val142Ile variant compared to 0% – 22% reported from the rest of the world (<a href="#T2" class="usa-link">Table 2</a>)<sup><a href="#R42" class="usa-link" aria-describedby="R42">42</a>–<a href="#R51" class="usa-link" aria-describedby="R51">51</a></sup>. Among studies of clinically diagnosed vATTR polyneuropathy the p.Val142Ile variant frequency was expectedly low ranging from 0% – 1.7% (<a href="#SD1" class="usa-link">Supplemental Table IV</a>)<sup><a href="#R52" class="usa-link" aria-describedby="R52">52</a>–<a href="#R61" class="usa-link" aria-describedby="R61">61</a></sup>.</p>
<section class="tw xbox font-sm" id="T2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p id="P67">p.Val142Ile Variant Frequency among vATTR-CM</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="all">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead><tr>
<th align="center" valign="middle" rowspan="1" colspan="1">Data Source, Location</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Time Period</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Proportion of ATTR-CM that is of African Descent</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Proportion of p.Val142Ile among vATTR-CM</th>
<th align="center" valign="middle" rowspan="1" colspan="1"></th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Kaiser San Francisco, USA<sup><a href="#R44" class="usa-link" aria-describedby="R44">44</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2001–2016</td>
<td align="center" valign="middle" rowspan="1" colspan="1">48% (32/67)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">79% (23/29)</td>
<td rowspan="6" align="center" valign="middle" colspan="1">
<strong>USA + UK</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">AG10 Trial; USA, Europe, South America<sup><a href="#R45" class="usa-link" aria-describedby="R45">45</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2018</td>
<td align="center" valign="middle" rowspan="1" colspan="1">20% (10/49)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">79% (11/14)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Johns Hopkins Hospital, USA<sup><a href="#R42" class="usa-link" aria-describedby="R42">42</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2003–2016</td>
<td align="center" valign="middle" rowspan="1" colspan="1">41% (23/56)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">75% (21/28)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Cleveland Clinic, USA<sup><a href="#R46" class="usa-link" aria-describedby="R46">46</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2002–2014</td>
<td align="center" valign="middle" rowspan="1" colspan="1">34% (57/169)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">73% (37/51)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">National Amyloidosis Centre, UK<sup><a href="#R43" class="usa-link" aria-describedby="R43">43</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2000–2019</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">66% (314/474)</td>
</tr>
<tr>
<td colspan="2" align="center" valign="middle" rowspan="1"></td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>20% – 48%</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>66% – 79%</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Peking Union Medical College, Beijing, China <sup><a href="#R48" class="usa-link" aria-describedby="R48">48</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/23)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/23)</td>
<td rowspan="6" align="center" valign="middle" colspan="1">
<strong>Rest of World</strong>
</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Henri-Mondor Hospital, Creteil, France<sup><a href="#R51" class="usa-link" aria-describedby="R51">51</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2009–2013</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">22% (8/36)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Aarhus University Hospital, Denmark<sup><a href="#R47" class="usa-link" aria-describedby="R47">47</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2015–2016</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/15)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/5)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Multiple cardiology clinics, Japan<sup><a href="#R50" class="usa-link" aria-describedby="R50">50</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2001–2012</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/32)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/10)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Heidelberg Amyloidosis Center, Germany<sup><a href="#R49" class="usa-link" aria-describedby="R49">49</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/8)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"></td>
<td align="center" valign="middle" rowspan="1" colspan="1"></td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0%</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>0% – 22%</strong>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="TFN3"><p id="P68">n/r: not reported; USA: United States of America; UK: United Kingdom; vATTR-CM: variant transthyretin amyloid cardiomyopathy</p></div></div></section></section><section id="S11"><h3 class="pmc_sec_title">Estimated Prevalence of p.Val142Ile Homozygotes</h3>
<p id="P14">The best estimate of homozygosity in the general population comes from the large GnomAD database, which showed that the majority of p.Val142Ile carriers are heterozygotes with only 0.72% of subjects estimated to be homozygous<sup><a href="#R14" class="usa-link" aria-describedby="R14">14</a></sup>. As expected, in clinical cohorts with an enriched population the percentage of homozygotes identified were found to be higher (<a href="#SD1" class="usa-link">Supplemental Table V</a>)<sup><a href="#R3" class="usa-link" aria-describedby="R3">3</a>,<a href="#R5" class="usa-link" aria-describedby="R5">5</a>,<a href="#R16" class="usa-link" aria-describedby="R16">16</a>–<a href="#R19" class="usa-link" aria-describedby="R19">19</a>,<a href="#R22" class="usa-link" aria-describedby="R22">22</a>–<a href="#R24" class="usa-link" aria-describedby="R24">24</a>,<a href="#R26" class="usa-link" aria-describedby="R26">26</a>,<a href="#R28" class="usa-link" aria-describedby="R28">28</a>,<a href="#R42" class="usa-link" aria-describedby="R42">42</a>,<a href="#R62" class="usa-link" aria-describedby="R62">62</a>–<a href="#R64" class="usa-link" aria-describedby="R64">64</a></sup>. For example, among endomyocardial biopsy confirmed p.Val142Ile vATTR-CM 6% – 10% were homozygotes<sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a>,<a href="#R42" class="usa-link" aria-describedby="R42">42</a></sup>. In comparison, 4% to 14% of subjects referred to an amyloidosis clinic who underwent TTR variant testing were homozygotes.</p>
<p id="P15">These should be interpreted with caution due to the low absolute number of subjects that will be identified and may not be applicable clinically in smaller practices. For example, among cohorts of African Americans in the general population in whom the TTR variant was screened, the prevalence of homozygotes ranges from 0% (0 of 17) – 20% (1 of 5). But if restricted to cohorts with at least 1000 subjects, it ranged from 1% to 3%.</p></section><section id="S12"><h3 class="pmc_sec_title">Association of the p.Val142Ile Variant with Incident Heart Failure</h3>
<p id="P16">The studies describing the increased rates of HF among p.Val142Ile variant carriers are summarized in <a href="#T3" class="usa-link">Table 3</a><sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a>,<a href="#R15" class="usa-link" aria-describedby="R15">15</a>,<a href="#R18" class="usa-link" aria-describedby="R18">18</a>,<a href="#R20" class="usa-link" aria-describedby="R20">20</a>,<a href="#R21" class="usa-link" aria-describedby="R21">21</a>,<a href="#R63" class="usa-link" aria-describedby="R63">63</a>,<a href="#R65" class="usa-link" aria-describedby="R65">65</a></sup>. Prospective cohorts estimated that the risk of incident HF ranges from 1.47 to 1.75. Quarta et al analyzed the Atherosclerosis Risk in Communities (ARIC) cohort, a prospective observational study of subjects &lt;65 years old with a median follow up time of 21.5 years where most subjects of African descent are from the Jackson, Mississippi area <sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup>. Incident HF, defined by a first HF hospitalization, was observed in 29% of p.Val142Ile carriers (1.59 cases/100 person-years) vs. 20% of non-carriers (1.12 cases/100 person-years; p=0.04) with a stratified hazard ratio (HR) of 1.47 [95% Confidence Interval (CI): 1.03 – 2.10]. One important caveat to this study is that only 37% of all subjects with any genotyping information were male, likely an underrepresentation as the majority of p.Val142Ile vATTR-CM reported cases are males, and only a minority of these included had an echocardiogram limiting full phenotypic assessment. Buxbaum et al analyzed the prospective Cardiovascular Health Study (CHS) cohort from North Carolina and found that TTR p.Val142Ile carriers represented 2.8% of African American individuals with HF, but almost 7 percent in the similar age and gender analysis<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup>. In the total population, the relative risk of developing HF in p.Val142Ile carriers is 2.62 [95% CI: 1.28 – 5.37]; however, in the post-hoc matched subset it was no longer statistically significant (1.75 [95% CI: 0.79 – 3.86]).</p>
<section class="tw xbox font-sm" id="T3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p id="P69">Effect of p.Val142Ile Variant on Development of Heart Failure</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="all">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead><tr>
<th align="center" valign="middle" rowspan="1" colspan="1">Data Source, Location</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Sample Size</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Effect size</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Details</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">ARIC Cohort, USA<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3856</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Stratified HR: 1.47 [95% CI: 1.03 to 2.10]</td>
<td align="left" valign="middle" rowspan="1" colspan="1">• Incident HF hospitalization was observed 29% of carriers (1.59 cases/100 person-years) vs. 20% of non-carriers (1.12 cases/100 person-years), p=0.04</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">CHS Cohort, USA<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">5201</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Relative Risk:<br>Total population: 2.62 [95% CI: 1.28 – 5.37]<br>Post-hoc matched subset: 1.75 [95% CI: 0.79 – 3.86]</td>
<td align="left" valign="middle" rowspan="1" colspan="1">• p.Val142Ile carriers represented 2.8% of African American individuals with HF, but almost 7 percent in the similar age and gender analysis.</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Penn Medicine BioBank, USA<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">3724</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Adjusted odds ratio: 1.6 [95% CI: 1.1–2.3]</td>
<td align="left" valign="middle" rowspan="1" colspan="1">• p.Val142Ile variant carriers had higher rates of HF than non-carriers (44% vs. 30%; p=0.006)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Mt. Sinai BioMe BioBank, USA<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">5970</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Adjusted odds ratio: 1.8 [95% CI: 1.2–2.7]</td>
<td align="left" valign="middle" rowspan="1" colspan="1">• p.Val142Ile variant was more commonly found in cases of HF compared to controls (2.6% vs. 1.8%; p=0.008)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">New York University &amp; Veterans Administration Clinic, USA<sup><a href="#R21" class="usa-link" aria-describedby="R21">21</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">383</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Relative risk: 2.0 [95% CI: 1.04 to 3.71]</td>
<td align="left" valign="middle" rowspan="1" colspan="1">• Among all subjects, 39% p.Val142Ile carriers had evidence of HF vs. 17% of matched controls; p=0.07)<br>• Among the subjects referred for echocardiography, there was a statistically significantly higher incidence of HF in p.Val142Ile carriers vs. controls.</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="TFN4"><p id="P70">ARIC: Atherosclerosis Risk in Communities; CHS: Cardiovascular Health Study; CI: Confidence interval; HF: Heart failure; HR: hazard ratio; n/r: not reported; USA: United States of America</p></div></div></section></section><section id="S13"><h3 class="pmc_sec_title">Penetrance of p.Val142Ile variant</h3>
<p id="P17">It is difficult to determine the true penetrance of the p.Val142Ile variant that leads to the development of the vATTR-CM phenotype from current published studies. Due to historical under-recognition of this disease most cohorts lack a detailed phenotypic assessment, which can lead to under-diagnosis of ATTR-CM, particularly in the absence of the severe phenotype on echocardiography. Furthermore, there is an age-dependent expression of this phenotype. This can lead to a wide range of estimates of penetrance as demonstrated by the analysis of one cross-sectional study by Damrauer et al of the Penn Medicine BioBank<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup>. Among 116 p.Val142Ile carriers of African ancestry greater than 50 years old the calculated penetrance could be as low as 8% if only subjects who were formally diagnosed with vATTR-CM were included as positive cases. In contrast 46% of all carriers had heart failure, but all did not undergo assessment for vATTR-CM. Similarly, in the prospective ARIC cohort, nearly 50% of carriers developed incident HF by age 75 but a formal detailed phenotypic assessment of etiology of HF was also not feasible <sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup>.</p></section><section id="S14"><h3 class="pmc_sec_title">Prevalence of p.Val142Ile vATTR-CM among adults with Heart Failure</h3>
<p id="P18">Among those with the p.Val142Ile variant in retrospective cohorts, the adjusted odds ratio for HF ranged from 1.6 to 1.8. Damrauer et al found that among African-Americans &gt;50 years old who were p.Val142Ile carriers in the Penn Medicine BioBank the odds ratio for having an International Classification of Disease (ICD) code for HF was 1.6 [95% CI: 1.06 – 2.3] after adjusting for age, sex, confounding by ancestry, hypertension, and myocardial infarction/coronary revascularization<sup><a href="#R20" class="usa-link" aria-describedby="R20">20</a></sup>. This was replicated in their case-control analysis of the Mt. Sinai BioMe BioBank (adjusted odds ratio: 1.8 [95% CI: 1.2 – 2.7]) where the p.Val142Ile variant was more common among cases compared to controls of African/Hispanic descent &gt;65 years old without an ICD code for HF (2.6% vs. 1.8%; p=0.008). As this was based on administrative ICD codes, it lacked the granularity to identify if vATTR-CM was the true etiology of HF. Nonetheless, supportive evidence could be extrapolated from the multicenter observational DISCOVERY study aimed to characterize the frequency of TTR variants among 1001 patients with a clinical or echocardiographic phenotype of cardiac amyloidosis<sup><a href="#R62" class="usa-link" aria-describedby="R62">62</a></sup>. They found that p.Val142Ile carriers made up 92% of all 74 carriers of a pathological TTR variant, the majority of whom were African Americans with New York Heart Association (NYHA) functional class II or above.</p>
<p id="P19">In a cohort from routine clinical care, Jacobson et al evaluated consecutive elderly African Americans predominantly referred for echocardiography in the New York City area and noted that p.Val142Ile carriers are twice as likely to have HF (relative risk 2.0 [95% CI: 1.04 – 3.71]<sup><a href="#R21" class="usa-link" aria-describedby="R21">21</a></sup>. Similarly, a UK study evaluated 1392 patients that presented to their HF clinic in London of whom 211 were of Afro-Caribbean descent<sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a></sup>. Among them 8.5% (18/211) were found to have the p.Val142Ile variant, and 100% were subsequently confirmed to have p.Val142Ile vATTR-CM.</p>
<p id="P20">The p.Val142Ile variant has even been identified within patients of African descent for whom ATTR-CM was believed to have been excluded. Arvanitis et al found that among 99 elderly African Americans with left ventricular (LV) wall thickness &gt;12 mm in whom ATTR-CM was already thought to have been excluded as a cause of HF, five had the p.Val142Ile variant and two were subsequently diagnosed with p.Val142Ile vATTR-CM<sup><a href="#R63" class="usa-link" aria-describedby="R63">63</a></sup>. In a sub-study of the BEST trial (Beta-Blocker Evaluation in Survival Trial) where a clinical diagnosis of ATTR-CM was also an exclusion criterion, 10% of subjects of African descent (13/207) &gt;60 years of age with an ejection fraction &lt;35% and NYHA Class III-IV were found to have the p.Val142Ile variant; but no further genotype-phenotype correlations were performed<sup><a href="#R65" class="usa-link" aria-describedby="R65">65</a></sup>.</p></section><section id="S15"><h3 class="pmc_sec_title">Demographics of p.Val142Ile vATTR-CM</h3>
<p id="P21">The demographics of p.Val142Ile vATTR-CM subjects are summarized in <a href="#T4" class="usa-link">Table 4</a><sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a>,<a href="#R24" class="usa-link" aria-describedby="R24">24</a>,<a href="#R25" class="usa-link" aria-describedby="R25">25</a>,<a href="#R27" class="usa-link" aria-describedby="R27">27</a>,<a href="#R28" class="usa-link" aria-describedby="R28">28</a>,<a href="#R43" class="usa-link" aria-describedby="R43">43</a>,<a href="#R64" class="usa-link" aria-describedby="R64">64</a>,<a href="#R66" class="usa-link" aria-describedby="R66">66</a>–<a href="#R70" class="usa-link" aria-describedby="R70">70</a></sup>. When excluding studies that enrolled all ethnicities, 75% to 100% of all p.Val142Ile vATTR-CM cases were of African descent. Swiecicki et al found median age of symptom onset was almost 6 years earlier at 64 years (10–90<sup>th</sup> percentile: 50–75 years) than the age of diagnosis<sup><a href="#R27" class="usa-link" aria-describedby="R27">27</a></sup>. Looking exclusively at cases in patients of African descent, Connors et al found a comparable mean age at diagnosis of 70.2 ± 7.3 years<sup><a href="#R28" class="usa-link" aria-describedby="R28">28</a></sup>. Reddi et al found that the mean age of diagnosis in homozygotes was 64 ± 6 years, almost 10 years younger than heterozygotes<sup><a href="#R64" class="usa-link" aria-describedby="R64">64</a></sup>. There is a predominance of males and unsurprisingly no studies were identified that evaluated the characteristics of p.Val142Ile vATTR-CM exclusively among females. Finally, the atrial fibrillation was detected in 25% – 38% of p.Val142Ile vATTR-CM subjects<sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a>,<a href="#R28" class="usa-link" aria-describedby="R28">28</a>,<a href="#R66" class="usa-link" aria-describedby="R66">66</a>–<a href="#R68" class="usa-link" aria-describedby="R68">68</a></sup>. This is lower than the reported rate of atrial fibrillation among wild type TTR amyloidosis cardiomyopathy (wtATTR-CM) of 40–60%<sup><a href="#R9" class="usa-link" aria-describedby="R9">9</a></sup>. There were no studies that specifically reported the burden of arrhythmias on ambulatory monitoring specifically to p.Val142Ile vATTR-CM.</p>
<section class="tw xbox font-sm" id="T4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p id="P71">Demographics of p.Val142Ile vATTR-CM</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="all">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead><tr>
<th align="center" valign="middle" rowspan="1" colspan="1">Study, Date</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Sample Size</th>
<th align="center" valign="middle" rowspan="1" colspan="1">African descent</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Age at diagnosis, years</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Age at enrollment, years</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Males</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Atrial Fibrillation</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Connors 2009 <sup><a href="#R28" class="usa-link" aria-describedby="R28">28</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">36</td>
<td align="center" valign="middle" rowspan="1" colspan="1">100% (36/36)<sup><a href="#TFN8" class="usa-link">§</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">70 <sup><a href="#TFN6" class="usa-link">Ɨ</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">78% (25/36)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">28% (8/29<a href="#TFN9" class="usa-link"><sup>*</sup></a>)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Ruberg 2012 <sup><a href="#R69" class="usa-link" aria-describedby="R69">69</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">11</td>
<td align="center" valign="middle" rowspan="1" colspan="1">100% (11/11)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">71 <sup><a href="#TFN6" class="usa-link">Ɨ</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">82% (9/11)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">27% (3/11)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Givens 2013 <sup><a href="#R66" class="usa-link" aria-describedby="R66">66</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">28</td>
<td align="center" valign="middle" rowspan="1" colspan="1">96% (27/28)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">71 <sup><a href="#TFN7" class="usa-link">#</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">82% (23/28)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">38% (10/28)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Reddi 2014 <sup><a href="#R64" class="usa-link" aria-describedby="R64">64</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">194</td>
<td align="center" valign="middle" rowspan="1" colspan="1">92% (44/48<a href="#TFN9" class="usa-link"><sup>*</sup></a>)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">68 <sup><a href="#TFN7" class="usa-link">#</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">83% (157/189<a href="#TFN9" class="usa-link"><sup>*</sup></a>)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Swiecicki 2015 <sup><a href="#R27" class="usa-link" aria-describedby="R27">27</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">28</td>
<td align="center" valign="middle" rowspan="1" colspan="1">75% (21/28)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">69 <sup><a href="#TFN7" class="usa-link">#</a></sup>
<br>64 (s)<sup><a href="#TFN7" class="usa-link">#</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">96% (27/28)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Maurer 2015 <sup><a href="#R67" class="usa-link" aria-describedby="R67">67</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">4</td>
<td align="center" valign="middle" rowspan="1" colspan="1">100% (4/4)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">73 <sup><a href="#TFN7" class="usa-link">#</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">75% (3/4)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">25% (1/4)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Dungu 2016 <sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">18</td>
<td align="center" valign="middle" rowspan="1" colspan="1">100% (18/18)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">71 <sup><a href="#TFN7" class="usa-link">#</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Maurer 2016 <sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">91</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">69 <sup><a href="#TFN6" class="usa-link">Ɨ</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">76% (69/91)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">30% (27/91)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Singh 2017 <sup><a href="#R70" class="usa-link" aria-describedby="R70">70</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">35</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">72 <sup><a href="#TFN6" class="usa-link">Ɨ</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Gentile 2020 <sup><a href="#R24" class="usa-link" aria-describedby="R24">24</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">5</td>
<td align="center" valign="middle" rowspan="1" colspan="1">0% (0/5) <sup><a href="#TFN8" class="usa-link">§</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">67 <sup><a href="#TFN6" class="usa-link">Ɨ</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Monfort 2020 <sup><a href="#R68" class="usa-link" aria-describedby="R68">68</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">18</td>
<td align="center" valign="middle" rowspan="1" colspan="1">100% (18/18) <sup><a href="#TFN8" class="usa-link">§</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">72 <sup><a href="#TFN6" class="usa-link">Ɨ</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">89% (16/18)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">33% (6/18)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Chacko 2020 <sup><a href="#R43" class="usa-link" aria-describedby="R43">43</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">314</td>
<td align="center" valign="middle" rowspan="1" colspan="1">87% (272/314)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="center" valign="middle" rowspan="1" colspan="1">75 <sup><a href="#TFN6" class="usa-link">Ɨ</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">73% (229/314)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1"></td>
<td align="center" valign="middle" rowspan="1" colspan="1"></td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>75% – 100%</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>67 – 71</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>69 – 75</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>73% – 96%</strong>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>25% – 38%</strong>
</td>
</tr>
<tr><td colspan="7" align="left" valign="middle" rowspan="1"></td></tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="TFN5"><p id="P72">(s) - age of symptom onset; vATTR-CM - variant transthyretin amyloid cardiomyopathy</p></div>
<div class="fn" id="TFN6">
<sup>Ɨ</sup><p class="display-inline" id="P73">average</p>
</div>
<div class="fn" id="TFN7">
<sup>#</sup><p class="display-inline" id="P74">median</p>
</div>
<div class="fn" id="TFN8">
<sup>§</sup><p class="display-inline" id="P75">Studies with single race/ancestry as inclusion criteria not included in range</p>
</div>
<div class="fn" id="TFN9">
<sup>*</sup><p class="display-inline" id="P76">incomplete data reported</p>
</div>
</div></section></section><section id="S16"><h3 class="pmc_sec_title">Quality of Life for p.Val142Ile vATTR-CM</h3>
<p id="P22">Given the progressive nature of ATTR-CM and the historical lack of any proven therapies, studies reporting on patients’ quality of life (QoL) demonstrated deterioration over time. Lane et al observed that the direction of change in Kansas City Cardiomyopathy Questionnaire (KCCQ) QoL scores was overwhelmingly negative in all ATTR-CM cohorts and in all QOL domains. p.Val142Ile vATTR-CM specifically showed clinically significant deterioration in seven out of ten domains, compared to five for non-p.Val142Ile vATTR-CM and three domains for wtATTR-CM<sup><a href="#R71" class="usa-link" aria-describedby="R71">71</a></sup>. Among the USA cohort of the THAOS (Transthyretin Amyloid Outcome Survey) worldwide registry, although the duration of disease approached that of other ATTR patients, p.Val142Ile carriers had worse NYHA functional class and worse QOL, as evidenced by lower Euro-Qual-5D index and lower Karnofsky performance<sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a></sup>.</p></section><section id="S17"><h3 class="pmc_sec_title">Effect of p.Val142Ile Variant on Survival and Clinical Outcomes of p.Val142Ile vATTR-CM</h3>
<p id="P23">The negative effect of p.Val142Ile variant on survival and the clinical outcomes of p.Val142Ile vATTR-CM are summarized in <a href="#T5" class="usa-link">Table 5</a>. Analysis of the CHS cohort found that the relative risk of death for cases with the p.Val142Ile variant is 2.59 [95% CI: 1.01 – 6.63] versus age matched controls after 15 years of follow up time <sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup>. The distribution of the recorded causes of death did not differ between groups. In contrast p.Val142Ile carriers in the ARIC cohort did not have an increased risk of death after 21.5 years (age and sex-stratified HR: 0.99 [95% CI: 0.73 – 1.36]<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup>. The differences between these studies are likely the result of variation in age and sex: CHS only enrolled subjects &gt;65 years old with 43% of them male, whereas ARIC consisted of subjects &lt;65 years old with 38% of them male. Although p.Val142Ile vATTR-CM subjects are most likely to be male, Lane et al did not find biological sex to be an independent predictor of mortality among their vATTR-CM cohort<sup><a href="#R71" class="usa-link" aria-describedby="R71">71</a></sup>.</p>
<section class="tw xbox font-sm" id="T5"><h4 class="obj_head">Table 5:</h4>
<div class="caption p"><p id="P77">Effect of p.Val142Ile Variant on Survival</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="box" rules="all">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead><tr>
<th align="center" valign="middle" rowspan="1" colspan="1">Data Source, Location</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Population Studied</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Effect Size</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Follow up time</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Details</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>CHS Cohort, USA</strong>
<sup><a href="#R18" class="usa-link" aria-describedby="R18">18</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">General Population</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Relative risk of death:<br> • Overall: 1.95 [95% CI: 0.92 – 4.14]<br> • Matched Cohort: 2.59 [95% CI: 1.01 – 6.63]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">15 years</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • The distribution of the recorded causes of death did not differ between groups.</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>ARIC Cohort, USA</strong>
<sup><a href="#R15" class="usa-link" aria-describedby="R15">15</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">General population</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Age and sex-stratified HR: 0.99 [95% CI: 0.73 – 1.36]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">21.5 years</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • p.V142I carriers: 1.76 deaths/100 person-years<br> • Non-carriers: 1.96 deaths/100 person-years</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>St. George Hospital, UK</strong>
<sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">HF Patients of Afro-Caribbean descent</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • ATTR p.V142I had the poorest survival (2.33 years) versus dilated and hypertensive CM, but no significant difference vs. ischemic or valvular CM</td>
<td align="center" valign="middle" rowspan="1" colspan="1">8 years</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Afro-Caribbean patients with p.V142I vATTR-CM presented at a relatively old median age of 76 years (IQR: 74 – 78)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Boston Medical Center, USA</strong>
<sup><a href="#R28" class="usa-link" aria-describedby="R28">28</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Cardiac Amyloidosis - African descent</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Survival estimates for p.V142I vATTR-CM vs. AL-CM:<br> • At 1 year: 79% vs 26%<br> • At 3 years: 48% vs 10%</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="left" valign="middle" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Kaiser San Francisco, USA</strong>
<sup><a href="#R44" class="usa-link" aria-describedby="R44">44</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Cardiac amyloidosis – ICD codes</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • In ATTR patients, African American race was associated with higher mortality</td>
<td align="center" valign="middle" rowspan="1" colspan="1">2.8 ± 2.9 years</td>
<td align="left" valign="middle" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Mayo Clinic, USA</strong>
<sup><a href="#R27" class="usa-link" aria-describedby="R27">27</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">vATTR</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Univariate RR: 1.76 (p&lt;0.05)<br> • Multivariate RR: 2.83 (p&lt;0.05)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">46 months (7.2 – 164.4)</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • The shortest survival was for p.V142I carriers as all had cardiac involvement at diagnosis</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>THAOS, USA cohort</strong>
<sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">ATTR</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Survival from enrollment in THAOS did not differ between p.V142I vATTR and wtATTR.</td>
<td align="center" valign="middle" rowspan="1" colspan="1">~24 months</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • 48/66 (73%) died at 24 months</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>NAC, UK</strong>
<sup><a href="#R26" class="usa-link" aria-describedby="R26">26</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">ATTR</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • 55% diagnosed with p.V142I ATTR died at end of follow up period</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Median age at death: 78 years (range 63–91)<br> • Median survival from diagnosis: 33 months (range 1–240)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>TRACS, USA</strong>
<sup><a href="#R69" class="usa-link" aria-describedby="R69">69</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">ATTR-CM</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • p.V142I were more likely to have died at end of follow up (73% vs 22%, p = 0.03)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Median survival<br> • wtATTR-CM: 43 months versus<br> • p.V142I vATTR-CM: 26 months (p = .04)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>NAC, UK</strong>
<sup><a href="#R71" class="usa-link" aria-describedby="R71">71</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">ATTR-CM</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Among African ancestry, median survival for p.Val142Ile vATTR-CM was 31 months vs. 40 months for wtATTR-CM (P=0.85)<br> • p.Val142Ile vATTR-CM multivariate HR for death 2.07 [95% CI: 1.415–3.031, p&lt;0.01]</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Median survival from diagnosis:<br>• p.Val142Ile vATTR-CM: 31 months vs.<br>• wtATTR-CM: 57 months vs.<br>• non–p.Val142Ile vATTR-CM: 69 months (p&lt;0.01)</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Columbia University, USA</strong>
<sup><a href="#R66" class="usa-link" aria-describedby="R66">66</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">ATTR-CM</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Among non-transplanted patients OR: 0.96 [95% CI: 0.31–3.01; p = 0.94]<br> • The median time to death alone was not significantly different.</td>
<td align="center" valign="middle" rowspan="1" colspan="1">n/r</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Median time from diagnosis to death/OHT:<br>• p.Val142Ile vATTR-CM: 36 months vs.<br>• wtATTR-CM: 67 months (p = 0.09)<br>Survival among those who did not undergo OHT:<br>• p.Val142Ile 32% (7/22) vs.<br>• wtATTR-CM 25% (8/36) (p = 0.4).<br>Mean age at death among p.Val142Ile: 73 ± 6.1 years</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">
<strong>Brigham and Women’s Hospital, Boston, USA</strong>
<sup><a href="#R70" class="usa-link" aria-describedby="R70">70</a></sup>
</td>
<td align="center" valign="middle" rowspan="1" colspan="1">ATTR-CM</td>
<td align="left" valign="middle" rowspan="1" colspan="1"> • Hazard ratio: 2.1 [95% CI: 1.2 – 3.6]</td>
<td align="center" valign="middle" rowspan="1" colspan="1"></td>
<td align="left" valign="middle" rowspan="1" colspan="1">Median time from diagnosis to death:<br>• p.Val142Ile vATTR-CM: 47 months vs.<br>• wtATTR-CM: 59 months (p = 0.09)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="TFN10"><p id="P78">ARIC: Atherosclerosis Risk in Communities; CHS: Cardiovascular Health Study; CI: Confidence interval; HF: Heart failure; HR: hazard ratio; n/r: not reported; NAC: National Amyloidosis Center; THAOS: Transthyretin Amyloid Outcome Survey; TRACS: Transthyretin Amyloidosis Cardiac Study; USA: United States of America; UK: United Kingdom; vATTR-CM: variant transthyretin cardiac amyloidosis</p></div></div></section><p id="P24">From the National Amyloidosis Center (NAC) in the UK, the median age at death of p.Val142Ile carriers was 78 years (range 63–91)<sup><a href="#R26" class="usa-link" aria-describedby="R26">26</a></sup>. There and at the Mayo Clinic it was found that p.Val142Ile carriers had the shortest median survival from diagnosis among all vATTR subgroups<sup><a href="#R26" class="usa-link" aria-describedby="R26">26</a>,<a href="#R27" class="usa-link" aria-describedby="R27">27</a></sup>. Conversely Maurer et al reported that survival two years from enrollment did not differ for p.Val142Ile vATTR cases in the USA cohort of the THAOS registry<sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a></sup>.</p>
<p id="P25">Patients of Afro-Caribbean descent with p.Val142Ile vATTR-CM at a HF clinic in London had significantly lower survival (2.33 years) compared to non-ischemic dilated cardiomyopathy (7.41 years, p&lt;0.001) and hypertensive heart disease (7.32 years, p=0.002), but there was no significant difference compared to ischemic heart disease or valvular heart disease<sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a></sup>. The conclusion was the difference may be driven by the median age of presentation, which was significantly higher for p.Val142Ile vATTR-CM (76 years; IQR 74–78) compared to dilated CM and hypertensive CM, but akin to ischemic CM and valvular CM. This study as well as other smaller single center studies showed a comparatively shorter median survival for p.Val142Ile vATTR-CM (<a href="#T5" class="usa-link">Table 5</a>)<sup><a href="#R66" class="usa-link" aria-describedby="R66">66</a>,<a href="#R69" class="usa-link" aria-describedby="R69">69</a>–<a href="#R71" class="usa-link" aria-describedby="R71">71</a></sup>.</p>
<p id="P26">Czobor et al identified all patients with cardiac amyloidosis using ICD codes at Kaiser Permanente hospital systems in San Francisco, USA and found that among all ATTR-CM patients, African American race was associated with higher mortality<sup><a href="#R44" class="usa-link" aria-describedby="R44">44</a></sup>.</p></section><section id="S18"><h3 class="pmc_sec_title">Orthotopic heart transplantation for p.Val142Ile vATTR-CM</h3>
<p id="P27">It is uncommon for patients with cardiac amyloidosis to undergo orthotopic heart transplantation (OHT), only comprising 0.14% of those performed in the USA, although p.Val142Ile vATTR-CM makes up a large proportion of these patients<sup><a href="#R72" class="usa-link" aria-describedby="R72">72</a>,<a href="#R73" class="usa-link" aria-describedby="R73">73</a></sup>. In the USA cohort of the THAOS registry, OHT was more frequently performed in p.Val142Ile carriers compared to wtATTR among the 11 who underwent OHT out of 330 symptomatic ATTR-CM patients<sup><a href="#R25" class="usa-link" aria-describedby="R25">25</a></sup>. Givens et al found that 28.6% (8/28) of p.Val142Ile vATTR-CM subjects received an OHT compared to 2.7% (1/37) wtATTR-CM subjects<sup><a href="#R66" class="usa-link" aria-describedby="R66">66</a></sup>. This was likely driven by eligibility for transplant and lower average age of diagnosis (60.7 ± 4.7 years) for the eight who received an OHT versus those who did not (73.5 ± 5.5; p=0.0001).</p></section></section><section id="S19"><h2 class="pmc_sec_title">Discussion</h2>
<p id="P28">In the USA, HF is more prevalent among African Americans than other races<sup><a href="#R74" class="usa-link" aria-describedby="R74">74</a></sup>. The Multi-Ethnic Study of Atherosclerosis (MESA) study revealed that African Americans also had the highest risk of incident HF<sup><a href="#R75" class="usa-link" aria-describedby="R75">75</a></sup>. Although it has been found that the greater proportion of HF risk was attributable to more traditional modifiable risk factors compared to those identified as white (68% vs. 49%), it is also important to identify and be familiar with non-modifiable risk factors for development of HF that are unique to those of African descent. The p.Val142Ile variant is one such risk factor that can appreciably contribute to the burden of HF, particularly in those with atypical presentations<sup><a href="#R76" class="usa-link" aria-describedby="R76">76</a></sup>. In HF clinics or among those at risk for HF, p.Val142Ile vATTR-CM was the etiology of 4–8% of the cases of HF<sup><a href="#R5" class="usa-link" aria-describedby="R5">5</a>,<a href="#R63" class="usa-link" aria-describedby="R63">63</a>,<a href="#R65" class="usa-link" aria-describedby="R65">65</a></sup>. It is thus important to raise awareness of this among clinicians to help better care for this population that has higher rates of hospitalization, higher rates of death after HF hospitalization, and higher age- adjusted death rates<sup><a href="#R74" class="usa-link" aria-describedby="R74">74</a>,<a href="#R77" class="usa-link" aria-describedby="R77">77</a>,<a href="#R78" class="usa-link" aria-describedby="R78">78</a></sup>.</p>
<p id="P29">The overall prevalence of the p.Val142Ile variant is low, but it appears to increase proportionally to the percentage of the population in the area studied who is of African descent. Thus, there appears to be a consistent linear relationship across studies with the p.Val142Ile prevalence increasing by 0.034% for every 1% increase in reported percentage of people of African descent in a region. This is expected given that the founder mutation likely originated in West Africa. The majority of eligible studies were in the USA or Western Europe, where most people of African descent were brought from Western Africa as a result of the African slave trade (<a href="#F1" class="usa-link">Figure 1</a>) <sup><a href="#R79" class="usa-link" aria-describedby="R79">79</a></sup>. This is the most plausible explanation for the geographical differences in prevalence, although increased healthcare utilization in more developed countries with increased use of diagnostic tools for amyloidosis may also play a role.</p>
<p id="P30">Based on the above prevalence and a Census Bureau estimate of the USA population, there are approximately 1.6 million African Americans who could be p.Val142Ile carriers, 160,000 of whom are &gt;65 years old<sup><a href="#R80" class="usa-link" aria-describedby="R80">80</a></sup>. Additionally, an increasing number of carriers will be diagnosed as more first-degree relatives undergo cascade genetic testing for the TTR variant. This should be an impetus to determine the true penetrance to develop vATTR-CM as well as study the utility of screening for the p.Val142Ile variant <sup><a href="#R80" class="usa-link" aria-describedby="R80">80</a></sup>. Although intuitively it would be assumed that the etiology of incident heart failure among p.Val142Ile carriers is vATTR-CM, this has not been confidently confirmed and thus the true penetrance has not yet been determined. Even in studies where the etiology was thought to have been determined, it is very plausible that the assumed etiology of HF could be incorrect as demonstrated by a sub-study of the BEST trial<sup><a href="#R65" class="usa-link" aria-describedby="R65">65</a></sup>. Among African Americans with NYHA class III and IV, where the diagnosis of cardiac amyloidosis was an exclusion criterion, 10% of subjects &gt;60 years old carried the p.Val142Ile variant. Factors that influence penetrance will also be valuable information, including epigenetic and gene-environment interactions that have been studied in other TTR variants<sup><a href="#R81" class="usa-link" aria-describedby="R81">81</a>,<a href="#R82" class="usa-link" aria-describedby="R82">82</a></sup>.</p>
<p id="P31">Screening will require educational and community grassroots efforts. There have been historically lower rates of genetic testing among African Americans with concerns about the potential misuse of genetic testing likely playing a role and hence <sup><a href="#R83" class="usa-link" aria-describedby="R83">83</a>–<a href="#R85" class="usa-link" aria-describedby="R85">85</a></sup>. African Americans have been subject to systemic injustice leading to socio-economic barriers that contribute to decreased healthcare utilization and lower rates of HF diagnosis <sup><a href="#R74" class="usa-link" aria-describedby="R74">74</a>,<a href="#R75" class="usa-link" aria-describedby="R75">75</a>,<a href="#R86" class="usa-link" aria-describedby="R86">86</a></sup>. Additionally when LV hypertrophy (LVH) is noted in people of African descent this is more likely to be attributed to hypertension compared to other races<sup><a href="#R87" class="usa-link" aria-describedby="R87">87</a></sup>. Educating physicians to carefully evaluate if there is an underlying etiology of LVH besides hypertension in patients of African descent will be a significant step in the right direction. There have not been well designed prospective studies testing strategies to screen for vATTR-CM, however the SCAN-MP (Screening for Cardiac Amyloidosis Using Nuclear Imaging for Minority Populations) trial represents a large effort aiming at answering this exact question <sup><a href="#R88" class="usa-link" aria-describedby="R88">88</a></sup>. With the advent of new imaging techniques to diagnose ATTR-CM, it will be easier to identify those with early vATTR-CM phenotype.</p>
<p id="P32">Earlier diagnosis is more important than ever given the introduction of therapeutics that appear to be more beneficial earlier in the disease course, as shown in the <em>ATTR-ACT</em> (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial) phase III randomized controlled trial of the tetramer stabilizer tafamidis, <sup><a href="#R10" class="usa-link" aria-describedby="R10">10</a></sup>. Recently, a prespecified analysis of <em>ATTR-ACT</em> showed that vATTR-CM patients (58% p.Val142Ile) had worse outcomes compared to wtATTR-CM <sup><a href="#R89" class="usa-link" aria-describedby="R89">89</a></sup>. In spite of the vATTR-CM patients being significantly younger, they had more severe disease at baseline with significantly fewer being NYHA Class I or II, lower 6-minute walk times, and higher NT-proBNP levels. This is particularly concerning as 52% of vATTR-CM patients were reported to be Black compared to 2% of wtATTR-CM. Although small and retrospective, an Italian study showed that p.Ile88Leu vATTR-CM patients (100% white) did not have a lower age-adjusted survival<sup><a href="#R90" class="usa-link" aria-describedby="R90">90</a></sup>. Despite other studies attempting to control for African ancestry, these current data raise the question of whether the worse outcomes in vATTR-CM is related to socio-economic disparities or due to the underlying disease itself. Regrettably, participants of African descent represented only 2% of the patients enrolled in the pivotal clinical studies that led to the approval of inotersen and patisiran in vATTR polyneuropathy and 14% of the population in <em>ATTR-ACT</em><sup><a href="#R80" class="usa-link" aria-describedby="R80">80</a></sup>. While executing clinical trials in ATTR-CM is a difficult task, intentional effort and specific steps should be taken to recruit a more diverse clinical trial population.</p>
<p id="P33">The basis for male predilection in p.Val142Ile vATTR-CM is not well described, but it is thought to be due to milder phenotypes in females on presentation when compared to males of the same age. Sex differences in LV function of p.Val142Ile vATTR-CM patients (37% female; 96% Black) were recently evaluated using non-invasive pressure-volume analysis by Batra et al<sup><a href="#R91" class="usa-link" aria-describedby="R91">91</a></sup>. They found that despite females being diagnosed eight years later they had similar LV function and mortality, which further suggests that females have a less aggressive disease trajectory, making vATTR-CM diagnosis even more difficult. Likewise, Gonzalez-Lopez et al found that females made up 50% of those diagnosed wtATTR-CM, by prospectively performing <sup>99m</sup>Tc-DPD (3,3-diphosphono-1,2-propanodicarboxylicacid) scintigraphy scans on consecutive elderly inpatients with LVH and unexplained HF with preserved ejection fraction<sup><a href="#R8" class="usa-link" aria-describedby="R8">8</a></sup>. This surprisingly high proportion of females may be explained by the older mean age of 86 years among all wtATTR-CM patients. There may be a pathophysiological basis for this observation. A mouse model showed that androgens increase hepatic TTR mRNA expression more than estrogen<sup><a href="#R92" class="usa-link" aria-describedby="R92">92</a></sup>. Rapezzi et al also showed that among vATTR-CM, females in the highest tertile of mean LV wall thickness were more often post-menopausal although none were p.Val142Ile carriers<sup><a href="#R93" class="usa-link" aria-describedby="R93">93</a></sup>; this is consistent with the published evidence demonstrating thinner LV walls when females present with ATTR-CM<sup><a href="#R94" class="usa-link" aria-describedby="R94">94</a></sup>. Finally, traditional sex disparities in cardiovascular outcomes, particularly for African American women may also contribute to this probable under-diagnosis<sup><a href="#R95" class="usa-link" aria-describedby="R95">95</a>,<a href="#R96" class="usa-link" aria-describedby="R96">96</a></sup>.</p>
<p id="P34">The heterogeneity in the methodology and data required for extraction is a limitation of this systematic literature review. We included both observational studies and prospective therapeutic trials. Given the heterogeneity we did not perform a meta-analysis and limited summary statistics to ranges. There was additional heterogeneity in terms of the stage at which patients were recruited into a study as well as in the reporting of statistics. Furthermore, many studies were excluded due to the lack of information on specific type of ATTR-CM and these excluded studies may have altered the results if they could have been reported. We assumed that all those identified as Black race were of African descent, which can be associated with inaccuracies given that the genetic ancestry was not individually defined. Conversely, studies of p.Val142Ile were included even if ancestry or race was not mentioned. The consistency in the extracted data across studies that were included was reassuring that despite these limitations it was likely represented accurately.</p></section><section id="S20"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="P35">The p.Val142Ile variant is the most common variant of the TTR gene with the majority of carriers being of African descent. The true penetrance to develop p.Val142Ile vATTR-CM is unknown, but it is associated with increased rates of incident heart failure and portends a lower overall survival. p.Val142Ile vATTR-CM is a frequent but under-recognized cause of HF among individuals of African descent and is associated with a worse overall survival and quality of life even compared to other causes of cardiac amyloidosis. It is paramount to increase awareness and diagnosis of p.Val142Ile ATTR-CM as the availability of newer therapeutics bring the promise of improving clinical outcomes in this historically disadvantaged population.</p></section><section id="SM1"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="SD1"><div class="caption p"><span>003356 - Supplemental Material</span></div>
<div class="media p" id="d40e815"><div class="caption">
<a href="/articles/instance/8530896/bin/NIHMS1731320-supplement-003356_-_Supplemental_Material.pdf" data-ga-action="click_feat_suppl" class="usa-link">NIHMS1731320-supplement-003356_-_Supplemental_Material.pdf</a><sup> (700.8KB, pdf) </sup>
</div></div></section></section><section id="S21" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p id="P36"><strong>Sources of Funding:</strong> Kevin Alexander is supported the American Heart Association-Amos Medical Faculty Development Program (19AMFDP34990036) and the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2TR003143.</p>
<p id="P37"><strong>Disclosures:</strong> Ahmad Masri received research grants from Pfizer, Akcea, and Ultromics (all paid to OHSU), and fee for advisory boards, steering committees, or consulting from Eidos, Ionis, Pfizer, Alnylam, and Cytokinetics. Pranav Chandrashekar is supported by an educational grant from Pfizer paid to OHSU. Kevin Alexander previously received an investigator-initiated grant from Pfizer and has served on scientific advisory boards for Alnylam, Eidos, and Pfizer.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Nonstandard Abbreviations and Acronyms:</h2>
<dl class="def-list">
<dt>ARIC</dt>
<dd><p id="P38">Atherosclerosis Risk in Communities</p></dd>
<dt>ATTR-ACT</dt>
<dd><p id="P39">Transthyretin Amyloidosis Cardiomyopathy Clinical Trial</p></dd>
<dt>BEST</dt>
<dd><p id="P40">Beta-Blocker Evaluation in Survival Trial</p></dd>
<dt>CHS</dt>
<dd><p id="P41">Cardiovascular Health Study cohort</p></dd>
<dt>CI</dt>
<dd><p id="P42">Confidence Interval</p></dd>
<dt>CM</dt>
<dd><p id="P43">Cardiomyopathy</p></dd>
<dt>HF</dt>
<dd><p id="P44">heart failure</p></dd>
<dt>ICD</dt>
<dd><p id="P45">International Classification of Disease</p></dd>
<dt>KCCQ</dt>
<dd><p id="P46">Kansas City Cardiomyopathy Questionnaire</p></dd>
<dt>LV</dt>
<dd><p id="P47">left ventricle</p></dd>
<dt>LVH</dt>
<dd><p id="P48">left ventricular hypertrophy</p></dd>
<dt>MESA</dt>
<dd><p id="P49">Multi-Ethnic Study of Atherosclerosis</p></dd>
<dt>NAC</dt>
<dd><p id="P50">National Amyloidosis Centre, UK</p></dd>
<dt>NYHA</dt>
<dd><p id="P51">New York Heart Association</p></dd>
<dt>OHT</dt>
<dd><p id="P52">orthotopic heart transplantation</p></dd>
<dt>QoL</dt>
<dd><p id="P53">Quality of Life</p></dd>
<dt>ROW</dt>
<dd><p id="P54">Rest of World</p></dd>
<dt>THAOS</dt>
<dd><p id="P55">Transthyretin Amyloid Outcome Survey</p></dd>
<dt>TTR</dt>
<dd><p id="P56">Transthyretin</p></dd>
<dt>USA</dt>
<dd><p id="P57">United States of America</p></dd>
<dt>UK</dt>
<dd><p id="P58">United Kingdom</p></dd>
<dt>vATTR</dt>
<dd><p id="P59">variant transthyretin amyloidosis</p></dd>
<dt>vATTR-CM</dt>
<dd><p id="P60">variant transthyretin amyloidosis cardiomyopathy</p></dd>
<dt>wtATTR-CM</dt>
<dd><p id="P61">wild-type transthyretin amyloidosis cardiomyopathy</p></dd>
</dl></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References:</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid
2015;22:171–4.</cite> [<a href="https://doi.org/10.3109/13506129.2015.1051219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26123279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Prevalence%20of%20the%20amyloidogenic%20transthyretin%20(TTR)%20V122I%20allele%20in%2014%E2%80%89333%20African-Americans&amp;author=DR%20Jacobson&amp;author=AA%20Alexander&amp;author=C%20Tagoe&amp;author=JN%20Buxbaum&amp;volume=22&amp;publication_year=2015&amp;pages=171-4&amp;pmid=26123279&amp;doi=10.3109/13506129.2015.1051219&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>Jacobson DR, Alexander AA, Tagoe C, Garvey WT, Williams SM, Tishkoff S, Modiano D, Sirima SB, Kalidi I, Toure A, et al. 
The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa. Mol Genet Genomic Med
2016;4:548–56.</cite> [<a href="https://doi.org/10.1002/mgg3.231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5023940/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27652282/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Genet%20Genomic%20Med&amp;title=The%20prevalence%20and%20distribution%20of%20the%20amyloidogenic%20transthyretin%20(TTR)%20V122I%20allele%20in%20Africa&amp;author=DR%20Jacobson&amp;author=AA%20Alexander&amp;author=C%20Tagoe&amp;author=WT%20Garvey&amp;author=SM%20Williams&amp;volume=4&amp;publication_year=2016&amp;pages=548-56&amp;pmid=27652282&amp;doi=10.1002/mgg3.231&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med
1997;336:466–73.</cite> [<a href="https://doi.org/10.1056/NEJM199702133360703" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9017939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Variant-sequence%20transthyretin%20(isoleucine%20122)%20in%20late-onset%20cardiac%20amyloidosis%20in%20black%20Americans&amp;author=DR%20Jacobson&amp;author=RD%20Pastore&amp;author=R%20Yaghoubian&amp;author=I%20Kane&amp;author=G%20Gallo&amp;volume=336&amp;publication_year=1997&amp;pages=466-73&amp;pmid=9017939&amp;doi=10.1056/NEJM199702133360703&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>Alexander KM, Orav J, Singh A, Jacob SA, Menon A, Padera RF, Kijewski MF, Liao R, Di Carli MF, Laubach JP, et al. 
Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis. JAMA cardiology
2018;3:865–70.</cite> [<a href="https://doi.org/10.1001/jamacardio.2018.2093" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6233639/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30046835/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20cardiology&amp;title=Geographic%20Disparities%20in%20Reported%20US%20Amyloidosis%20Mortality%20From%201979%20to%202015:%20Potential%20Underdetection%20of%20Cardiac%20Amyloidosis&amp;author=KM%20Alexander&amp;author=J%20Orav&amp;author=A%20Singh&amp;author=SA%20Jacob&amp;author=A%20Menon&amp;volume=3&amp;publication_year=2018&amp;pages=865-70&amp;pmid=30046835&amp;doi=10.1001/jamacardio.2018.2093&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>Dungu JN, Papadopoulou SA, Wykes K, Mahmood I, Marshall J, Valencia O, Fontana M, Whelan CJ, Gillmore JD, Hawkins PN, et al. 
Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis. Circ Heart Fail
2016;9.</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.116.003352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27618855/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Heart%20Fail&amp;title=Afro-Caribbean%20Heart%20Failure%20in%20the%20United%20Kingdom:%20Cause,%20Outcomes,%20and%20ATTR%20V122I%20Cardiac%20Amyloidosis&amp;author=JN%20Dungu&amp;author=SA%20Papadopoulou&amp;author=K%20Wykes&amp;author=I%20Mahmood&amp;author=J%20Marshall&amp;publication_year=2016&amp;pages=9&amp;pmid=27618855&amp;doi=10.1161/CIRCHEARTFAILURE.116.003352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, et al. 
Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol
2018;72:2040–50.</cite> [<a href="https://doi.org/10.1016/j.jacc.2018.07.092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30336828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Tenosynovial%20and%20Cardiac%20Amyloidosis%20in%20Patients%20Undergoing%20Carpal%20Tunnel%20Release&amp;author=BW%20Sperry&amp;author=BA%20Reyes&amp;author=A%20Ikram&amp;author=JP%20Donnelly&amp;author=D%20Phelan&amp;volume=72&amp;publication_year=2018&amp;pages=2040-50&amp;pmid=30336828&amp;doi=10.1016/j.jacc.2018.07.092&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>Rosenblum H, Masri A, Narotsky DL, Goldsmith J, Hamid N, Hahn RT, Kodali S, Vahl T, Nazif T, Khalique OK, et al. 
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail
2020.</cite> [<a href="https://doi.org/10.1002/ejhf.1974" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32729170/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Unveiling%20outcomes%20in%20coexisting%20severe%20aortic%20stenosis%20and%20transthyretin%20cardiac%20amyloidosis&amp;author=H%20Rosenblum&amp;author=A%20Masri&amp;author=DL%20Narotsky&amp;author=J%20Goldsmith&amp;author=N%20Hamid&amp;publication_year=2020&amp;pmid=32729170&amp;doi=10.1002/ejhf.1974&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, et al. 
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J
2015;36:2585–94.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehv338" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26224076/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Wild-type%20transthyretin%20amyloidosis%20as%20a%20cause%20of%20heart%20failure%20with%20preserved%20ejection%20fraction&amp;author=E%20Gonz%C3%A1lez-L%C3%B3pez&amp;author=M%20Gallego-Delgado&amp;author=G%20Guzzo-Merello&amp;author=FJ%20de%20Haro-del%20Moral&amp;author=M%20Cobo-Marcos&amp;volume=36&amp;publication_year=2015&amp;pages=2585-94&amp;pmid=26224076&amp;doi=10.1093/eurheartj/ehv338&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol
2019;73:2872–91.</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6724183/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31171094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Transthyretin%20Amyloid%20Cardiomyopathy:%20JACC%20State-of-the-Art%20Review&amp;author=FL%20Ruberg&amp;author=M%20Grogan&amp;author=M%20Hanna&amp;author=JW%20Kelly&amp;author=MS%20Maurer&amp;volume=73&amp;publication_year=2019&amp;pages=2872-91&amp;pmid=31171094&amp;doi=10.1016/j.jacc.2019.04.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, et al. 
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med
2018;379:1007–16.</cite> [<a href="https://doi.org/10.1056/NEJMoa1805689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30145929/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Tafamidis%20Treatment%20for%20Patients%20with%20Transthyretin%20Amyloid%20Cardiomyopathy&amp;author=MS%20Maurer&amp;author=JH%20Schwartz&amp;author=B%20Gundapaneni&amp;author=PM%20Elliott&amp;author=G%20Merlini&amp;volume=379&amp;publication_year=2018&amp;pages=1007-16&amp;pmid=30145929&amp;doi=10.1056/NEJMoa1805689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>Dasgupta NR, Benson MD. Potential Reversal of Transthyretin Amyloid Cardiomyopathy with Ttr Specific Antisense Oligonucleotide Therapy. J Am Coll Cardiol
2018;71:A660.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Potential%20Reversal%20of%20Transthyretin%20Amyloid%20Cardiomyopathy%20with%20Ttr%20Specific%20Antisense%20Oligonucleotide%20Therapy&amp;author=NR%20Dasgupta&amp;author=MD%20Benson&amp;volume=71&amp;publication_year=2018&amp;pages=A660&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH, 3rd, et al. 
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation
2019;139:431–43.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.118.035831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12611557/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30586695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Effects%20of%20Patisiran,%20an%20RNA%20Interference%20Therapeutic,%20on%20Cardiac%20Parameters%20in%20Patients%20With%20Hereditary%20Transthyretin-Mediated%20Amyloidosis&amp;author=SD%20Solomon&amp;author=D%20Adams&amp;author=A%20Kristen&amp;author=M%20Grogan&amp;author=A%20Gonz%C3%A1lez-Duarte&amp;volume=139&amp;publication_year=2019&amp;pages=431-43&amp;pmid=30586695&amp;doi=10.1161/CIRCULATIONAHA.118.035831&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. 2009;151:264–9.</cite> [<a href="https://doi.org/10.7326/0003-4819-151-4-200908180-00135" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19622511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Preferred%20Reporting%20Items%20for%20Systematic%20Reviews%20and%20Meta-Analyses:%20The%20PRISMA%20Statement&amp;volume=151&amp;publication_year=2009&amp;pages=264-9&amp;pmid=19622511&amp;doi=10.7326/0003-4819-151-4-200908180-00135&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>Lahuerta Pueyo C, Aibar Arregui MA, Gracia Gutierrez A, Bueno Juana E, Menao Guillen S. Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data. Eur J Hum Genet
2019;27:783–91.</cite> [<a href="https://doi.org/10.1038/s41431-019-0337-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6461877/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30683924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Hum%20Genet&amp;title=Estimating%20the%20prevalence%20of%20allelic%20variants%20in%20the%20transthyretin%20gene%20by%20analysing%20large-scale%20sequencing%20data&amp;author=C%20Lahuerta%20Pueyo&amp;author=MA%20Aibar%20Arregui&amp;author=A%20Gracia%20Gutierrez&amp;author=E%20Bueno%20Juana&amp;author=S%20Menao%20Guillen&amp;volume=27&amp;publication_year=2019&amp;pages=783-91&amp;pmid=30683924&amp;doi=10.1038/s41431-019-0337-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med
2015;372:21–9.</cite> [<a href="https://doi.org/10.1056/NEJMoa1404852" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4382209/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25551524/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=The%20amyloidogenic%20V122I%20transthyretin%20variant%20in%20elderly%20black%20Americans&amp;author=CC%20Quarta&amp;author=JN%20Buxbaum&amp;author=AM%20Shah&amp;author=RH%20Falk&amp;author=B%20Claggett&amp;volume=372&amp;publication_year=2015&amp;pages=21-9&amp;pmid=25551524&amp;doi=10.1056/NEJMoa1404852&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid
2005;12:127–30.</cite> [<a href="https://doi.org/10.1080/13506120500107162" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16011990/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=A%20prospective%20evaluation%20of%20the%20transthyretin%20Ile122%20allele%20frequency%20in%20an%20African-American%20population&amp;author=T%20Yamashita&amp;author=K%20Hamidi%20Asl&amp;author=M%20Yazaki&amp;author=MD%20Benson&amp;volume=12&amp;publication_year=2005&amp;pages=127-30&amp;pmid=16011990&amp;doi=10.1080/13506120500107162&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>Afolabi I, Hamidi Asl K, Nakamura M, Jacobs P, Hendrie H, Benson MD. Transthyretin isoleucine-122 mutation in African and American blacks. Amyloid
2000;7:121–5.</cite> [<a href="https://doi.org/10.3109/13506120009146249" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10842715/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Transthyretin%20isoleucine-122%20mutation%20in%20African%20and%20American%20blacks&amp;author=I%20Afolabi&amp;author=K%20Hamidi%20Asl&amp;author=M%20Nakamura&amp;author=P%20Jacobs&amp;author=H%20Hendrie&amp;volume=7&amp;publication_year=2000&amp;pages=121-5&amp;pmid=10842715&amp;doi=10.3109/13506120009146249&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J
2010;159:864–70.</cite> [<a href="https://doi.org/10.1016/j.ahj.2010.02.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2865207/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20435197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J&amp;title=Significance%20of%20the%20amyloidogenic%20transthyretin%20Val%20122%20Ile%20allele%20in%20African%20Americans%20in%20the%20Arteriosclerosis%20Risk%20in%20Communities%20(ARIC)%20and%20Cardiovascular%20Health%20(CHS)%20Studies&amp;author=J%20Buxbaum&amp;author=A%20Alexander&amp;author=J%20Koziol&amp;author=C%20Tagoe&amp;author=E%20Fox&amp;volume=159&amp;publication_year=2010&amp;pages=864-70&amp;pmid=20435197&amp;doi=10.1016/j.ahj.2010.02.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid
2008;15:255–61.</cite> [<a href="https://doi.org/10.1080/13506120802525285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5612502/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19065297/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Serum%20transthyretin%20levels%20in%20senile%20systemic%20amyloidosis:%20effects%20of%20age,%20gender%20and%20ethnicity&amp;author=J%20Buxbaum&amp;author=J%20Koziol&amp;author=LH%20Connors&amp;volume=15&amp;publication_year=2008&amp;pages=255-61&amp;pmid=19065297&amp;doi=10.1080/13506120802525285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, Dobbyn A, Guerraty MA, Judy R, Kay J, et al. 
Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA
2019;322:2191–202.</cite> [<a href="https://doi.org/10.1001/jama.2019.17935" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7081752/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31821430/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Association%20of%20the%20V122I%20Hereditary%20Transthyretin%20Amyloidosis%20Genetic%20Variant%20With%20Heart%20Failure%20Among%20Individuals%20of%20African%20or%20Hispanic/Latino%20Ancestry&amp;author=SM%20Damrauer&amp;author=K%20Chaudhary&amp;author=JH%20Cho&amp;author=LW%20Liang&amp;author=E%20Argulian&amp;volume=322&amp;publication_year=2019&amp;pages=2191-202&amp;pmid=31821430&amp;doi=10.1001/jama.2019.17935&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am J Cardiol
2011;108:440–4.</cite> [<a href="https://doi.org/10.1016/j.amjcard.2011.03.069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21600538/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&amp;title=Relation%20of%20clinical,%20echocardiographic%20and%20electrocardiographic%20features%20of%20cardiac%20amyloidosis%20to%20the%20presence%20of%20the%20transthyretin%20V122I%20allele%20in%20older%20African-American%20men&amp;author=D%20Jacobson&amp;author=C%20Tagoe&amp;author=A%20Schwartzbard&amp;author=A%20Shah&amp;author=J%20Koziol&amp;volume=108&amp;publication_year=2011&amp;pages=440-4&amp;pmid=21600538&amp;doi=10.1016/j.amjcard.2011.03.069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>Jacobson DR, Pastore R, Pool S, Malendowicz S, Kane I, Shivji A, Embury SH, Ballas SK, Buxbaum JN. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet
1996;98:236–8.</cite> [<a href="https://doi.org/10.1007/s004390050199" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8698351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum%20Genet&amp;title=Revised%20transthyretin%20Ile%20122%20allele%20frequency%20in%20African-Americans&amp;author=DR%20Jacobson&amp;author=R%20Pastore&amp;author=S%20Pool&amp;author=S%20Malendowicz&amp;author=I%20Kane&amp;volume=98&amp;publication_year=1996&amp;pages=236-8&amp;pmid=8698351&amp;doi=10.1007/s004390050199&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>Polimanti R, Nunez YZ, Gelernter J. Increased Risk of Multiple Outpatient Surgeries in African-American Carriers of Transthyretin Val122Ile Mutation Is Modulated by Non-Coding Variants. J Clin Med
2019;8.</cite> [<a href="https://doi.org/10.3390/jcm8020269" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6406512/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30813263/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=Increased%20Risk%20of%20Multiple%20Outpatient%20Surgeries%20in%20African-American%20Carriers%20of%20Transthyretin%20Val122Ile%20Mutation%20Is%20Modulated%20by%20Non-Coding%20Variants&amp;author=R%20Polimanti&amp;author=YZ%20Nunez&amp;author=J%20Gelernter&amp;publication_year=2019&amp;pages=8&amp;pmid=30813263&amp;doi=10.3390/jcm8020269&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>Gentile L, Di Bella G, Minutoli F, Cucinotta F, Obici L, Mussinelli R, Arimatea I, Russo M, Toscano A, Vita G, et al. 
Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features. J Peripher Nerv Syst
2020.</cite> [<a href="https://doi.org/10.1111/jns.12385" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32395865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Peripher%20Nerv%20Syst&amp;title=Description%20of%20a%20large%20cohort%20of%20Caucasian%20patients%20with%20V122I%20ATTRv%20amyloidosis:%20Neurological%20and%20cardiological%20features&amp;author=L%20Gentile&amp;author=G%20Di%20Bella&amp;author=F%20Minutoli&amp;author=F%20Cucinotta&amp;author=L%20Obici&amp;publication_year=2020&amp;pmid=32395865&amp;doi=10.1111/jns.12385&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, et al. 
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol
2016;68:161–72.</cite> [<a href="https://doi.org/10.1016/j.jacc.2016.03.596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4940135/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27386769/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Genotype%20and%20Phenotype%20of%20Transthyretin%20Cardiac%20Amyloidosis:%20THAOS%20(Transthyretin%20Amyloid%20Outcome%20Survey)&amp;author=MS%20Maurer&amp;author=M%20Hanna&amp;author=M%20Grogan&amp;author=A%20Dispenzieri&amp;author=R%20Witteles&amp;volume=68&amp;publication_year=2016&amp;pages=161-72&amp;pmid=27386769&amp;doi=10.1016/j.jacc.2016.03.596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, Baginska A, Ferguson SM, Gilbertson J, Rezk T, et al. 
Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat
2019;40:90–6.</cite> [<a href="https://doi.org/10.1002/humu.23669" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30328212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum%20Mutat&amp;title=Analysis%20of%20the%20TTR%20gene%20in%20the%20investigation%20of%20amyloidosis:%20A%2025-year%20single%20UK%20center%20experience&amp;author=D%20Rowczenio&amp;author=CC%20Quarta&amp;author=M%20Fontana&amp;author=CJ%20Whelan&amp;author=A%20Martinez-Naharro&amp;volume=40&amp;publication_year=2019&amp;pages=90-6&amp;pmid=30328212&amp;doi=10.1002/humu.23669&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>Swiecicki PL, Zhen DB, Mauermann ML, Kyle RA, Zeldenrust SR, Grogan M, Dispenzieri A, Gertz MA. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid
2015;22:123–31.</cite> [<a href="https://doi.org/10.3109/13506129.2015.1019610" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26017327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Hereditary%20ATTR%20amyloidosis:%20a%20single-institution%20experience%20with%20266%20patients&amp;author=PL%20Swiecicki&amp;author=DB%20Zhen&amp;author=ML%20Mauermann&amp;author=RA%20Kyle&amp;author=SR%20Zeldenrust&amp;volume=22&amp;publication_year=2015&amp;pages=123-31&amp;pmid=26017327&amp;doi=10.3109/13506129.2015.1019610&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O’Hara C, Seldin DC, et al. 
Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J
2009;158:607–14.</cite> [<a href="https://doi.org/10.1016/j.ahj.2009.08.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19781421/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J&amp;title=Cardiac%20amyloidosis%20in%20African%20Americans:%20comparison%20of%20clinical%20and%20laboratory%20features%20of%20transthyretin%20V122I%20amyloidosis%20and%20immunoglobulin%20light%20chain%20amyloidosis&amp;author=LH%20Connors&amp;author=T%20Prokaeva&amp;author=A%20Lim&amp;author=R%20Th%C3%A9berge&amp;author=RH%20Falk&amp;volume=158&amp;publication_year=2009&amp;pages=607-14&amp;pmid=19781421&amp;doi=10.1016/j.ahj.2009.08.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, et al. 
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J
2013;34:520–8.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehs123" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22745357/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Disease%20profile%20and%20differential%20diagnosis%20of%20hereditary%20transthyretin-related%20amyloidosis%20with%20exclusively%20cardiac%20phenotype:%20an%20Italian%20perspective&amp;author=C%20Rapezzi&amp;author=CC%20Quarta&amp;author=L%20Obici&amp;author=F%20Perfetto&amp;author=S%20Longhi&amp;volume=34&amp;publication_year=2013&amp;pages=520-8&amp;pmid=22745357&amp;doi=10.1093/eurheartj/ehs123&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>Hirakawa K, Takashio S, Marume K, Yamamoto M, Hanatani S, Yamamoto E, Sakamoto K, Izumiya Y, Kaikita K, Oda S, et al. 
Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis. ESC heart failure
2019;6:122–30.</cite> [<a href="https://doi.org/10.1002/ehf2.12361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6352919/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30284755/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESC%20heart%20failure&amp;title=Non-Val30Met%20mutation,%20septal%20hypertrophy,%20and%20cardiac%20denervation%20in%20patients%20with%20mutant%20transthyretin%20amyloidosis&amp;author=K%20Hirakawa&amp;author=S%20Takashio&amp;author=K%20Marume&amp;author=M%20Yamamoto&amp;author=S%20Hanatani&amp;volume=6&amp;publication_year=2019&amp;pages=122-30&amp;pmid=30284755&amp;doi=10.1002/ehf2.12361&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>Chao HC, Liao YC, Liu YT, Guo YC, Chang FP, Lee YC, Lin KP. Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan. Annals of clinical and translational neurology
2019;6:913–22.</cite> [<a href="https://doi.org/10.1002/acn3.778" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6529922/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31139689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20clinical%20and%20translational%20neurology&amp;title=Clinical%20and%20genetic%20profiles%20of%20hereditary%20transthyretin%20amyloidosis%20in%20Taiwan&amp;author=HC%20Chao&amp;author=YC%20Liao&amp;author=YT%20Liu&amp;author=YC%20Guo&amp;author=FP%20Chang&amp;volume=6&amp;publication_year=2019&amp;pages=913-22&amp;pmid=31139689&amp;doi=10.1002/acn3.778&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, van Veldhuisen DJ, Hazenberg BPC. Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. Am J Cardiol
2018;121:107–12.</cite> [<a href="https://doi.org/10.1016/j.amjcard.2017.09.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29153245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&amp;title=Frequency%20of%20and%20Prognostic%20Significance%20of%20Cardiac%20Involvement%20at%20Presentation%20in%20Hereditary%20Transthyretin-Derived%20Amyloidosis%20and%20the%20Value%20of%20N-Terminal%20Pro-B-Type%20Natriuretic%20Peptide&amp;author=SHC%20Klaassen&amp;author=J%20Tromp&amp;author=HLA%20Nienhuis&amp;author=P%20van%20der%20Meer&amp;author=MP%20van%20den%20Berg&amp;volume=121&amp;publication_year=2018&amp;pages=107-12&amp;pmid=29153245&amp;doi=10.1016/j.amjcard.2017.09.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R33">
<span class="label">33.</span><cite>Henein MY, Suhr OB, Arvidsson S, Pilebro B, Westermark P, Hörnsten R, Lindqvist P. Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis. Amyloid
2018;25:46–53.</cite> [<a href="https://doi.org/10.1080/13506129.2018.1430027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29369708/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Reduced%20left%20atrial%20myocardial%20deformation%20irrespective%20of%20cavity%20size:%20a%20potential%20cause%20for%20atrial%20arrhythmia%20in%20hereditary%20transthyretin%20amyloidosis&amp;author=MY%20Henein&amp;author=OB%20Suhr&amp;author=S%20Arvidsson&amp;author=B%20Pilebro&amp;author=P%20Westermark&amp;volume=25&amp;publication_year=2018&amp;pages=46-53&amp;pmid=29369708&amp;doi=10.1080/13506129.2018.1430027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>Auer-Grumbach M, Rettl R, Ablasser K, Agis H, Beetz C, Duca F, Gattermeier M, Glaser F, Hacker M, Kain R, et al. 
Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. J Clin Med
2020;9.</cite> [<a href="https://doi.org/10.3390/jcm9072234" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7408866/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32674397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=Hereditary%20ATTR%20Amyloidosis%20in%20Austria:%20Prevalence%20and%20Epidemiological%20Hot%20Spots&amp;author=M%20Auer-Grumbach&amp;author=R%20Rettl&amp;author=K%20Ablasser&amp;author=H%20Agis&amp;author=C%20Beetz&amp;publication_year=2020&amp;pages=9&amp;pmid=32674397&amp;doi=10.3390/jcm9072234&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>Cappelli F, Frusconi S, Bergesio F, Grifoni E, Fabbri A, Giuliani C, Falconi S, Bonifacio S, Perfetto F. The Val142Ile transthyretin cardiac amyloidosis: not only an Afro-American pathogenic variant? A single-centre Italian experience. J Cardiovasc Med (Hagerstown)
2016;17:122–5.</cite> [<a href="https://doi.org/10.2459/JCM.0000000000000290" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26428663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Med%20(Hagerstown)&amp;title=The%20Val142Ile%20transthyretin%20cardiac%20amyloidosis:%20not%20only%20an%20Afro-American%20pathogenic%20variant?%20A%20single-centre%20Italian%20experience&amp;author=F%20Cappelli&amp;author=S%20Frusconi&amp;author=F%20Bergesio&amp;author=E%20Grifoni&amp;author=A%20Fabbri&amp;volume=17&amp;publication_year=2016&amp;pages=122-5&amp;pmid=26428663&amp;doi=10.2459/JCM.0000000000000290&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid
2012;19
Suppl 1:34–6.</cite> [<a href="https://doi.org/10.3109/13506129.2012.678508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22551192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Doxycycline%20plus%20tauroursodeoxycholic%20acid%20for%20transthyretin%20amyloidosis:%20a%20phase%20II%20study&amp;author=L%20Obici&amp;author=A%20Cortese&amp;author=A%20Lozza&amp;author=J%20Lucchetti&amp;author=M%20Gobbi&amp;volume=19&amp;issue=Suppl%201&amp;publication_year=2012&amp;pages=34-6&amp;pmid=22551192&amp;doi=10.3109/13506129.2012.678508&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>Bartier S, Bodez D, Kharoubi M, Guellich A, Canoui-Poitrine F, Chatelin V, Coste A, Damy T, Bequignon E. Association between hearing loss and hereditary ATTR amyloidosis. Amyloid
2019;26:234–42.</cite> [<a href="https://doi.org/10.1080/13506129.2019.1663814" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31502881/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Association%20between%20hearing%20loss%20and%20hereditary%20ATTR%20amyloidosis&amp;author=S%20Bartier&amp;author=D%20Bodez&amp;author=M%20Kharoubi&amp;author=A%20Guellich&amp;author=F%20Canoui-Poitrine&amp;volume=26&amp;publication_year=2019&amp;pages=234-42&amp;pmid=31502881&amp;doi=10.1080/13506129.2019.1663814&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>Jang MA, Lee GY, Kim K, Kim SJ, Kim JS, Lee SY, Kim HJ, Jeon ES. Asp58Ala is the predominant mutation of the TTR gene in Korean patients with hereditary transthyretin-related amyloidosis. Ann Hum Genet
2015;79:99–107.</cite> [<a href="https://doi.org/10.1111/ahg.12101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25644864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Hum%20Genet&amp;title=Asp58Ala%20is%20the%20predominant%20mutation%20of%20the%20TTR%20gene%20in%20Korean%20patients%20with%20hereditary%20transthyretin-related%20amyloidosis&amp;author=MA%20Jang&amp;author=GY%20Lee&amp;author=K%20Kim&amp;author=SJ%20Kim&amp;author=JS%20Kim&amp;volume=79&amp;publication_year=2015&amp;pages=99-107&amp;pmid=25644864&amp;doi=10.1111/ahg.12101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R39">
<span class="label">39.</span><cite>Koike H, Nakamura T, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G. Widespread Cardiac and Vasomotor Autonomic Dysfunction in Non-Val30Met Hereditary Transthyretin Amyloidosis. Intern Med
2018;57:3365–70.</cite> [<a href="https://doi.org/10.2169/internalmedicine.1113-18" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6306549/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29984770/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Intern%20Med&amp;title=Widespread%20Cardiac%20and%20Vasomotor%20Autonomic%20Dysfunction%20in%20Non-Val30Met%20Hereditary%20Transthyretin%20Amyloidosis&amp;author=H%20Koike&amp;author=T%20Nakamura&amp;author=R%20Nishi&amp;author=S%20Ikeda&amp;author=Y%20Kawagashira&amp;volume=57&amp;publication_year=2018&amp;pages=3365-70&amp;pmid=29984770&amp;doi=10.2169/internalmedicine.1113-18&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R40">
<span class="label">40.</span><cite>Meng L-C, Lyu H, Zhang W, Liu J, Wang Z-X, Yuan Y. Hereditary Transthyretin Amyloidosis in Eight Chinese Families. Chin Med J
2015;128:2902–5.</cite> [<a href="https://doi.org/10.4103/0366-6999.168048" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4756886/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26521788/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Chin%20Med%20J&amp;title=Hereditary%20Transthyretin%20Amyloidosis%20in%20Eight%20Chinese%20Families&amp;author=L-C%20Meng&amp;author=H%20Lyu&amp;author=W%20Zhang&amp;author=J%20Liu&amp;author=Z-X%20Wang&amp;volume=128&amp;publication_year=2015&amp;pages=2902-5&amp;pmid=26521788&amp;doi=10.4103/0366-6999.168048&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R41">
<span class="label">41.</span><cite>Eriksson M, Buttner J, Todorov T, Yumlu S, Schonland S, Hegenbart U, Kristen AV, Dengler T, Lohse P, Helmke B, et al. 
Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid. Am J Surg Pathol
2009;33:58–65.</cite> [<a href="https://doi.org/10.1097/PAS.0b013e3181788566" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18830126/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Surg%20Pathol&amp;title=Prevalence%20of%20germline%20mutations%20in%20the%20TTR%20gene%20in%20a%20consecutive%20series%20of%20surgical%20pathology%20specimens%20with%20ATTR%20amyloid&amp;author=M%20Eriksson&amp;author=J%20Buttner&amp;author=T%20Todorov&amp;author=S%20Yumlu&amp;author=S%20Schonland&amp;volume=33&amp;publication_year=2009&amp;pages=58-65&amp;pmid=18830126&amp;doi=10.1097/PAS.0b013e3181788566&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R42">
<span class="label">42.</span><cite>Brown EE, Lee YZJ, Halushka MK, Steenbergen C, Johnson NM, Almansa J, Tedford RJ, Cingolani O, Russell SD, Sharma K, et al. 
Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid
2017;24:92–5.</cite> [<a href="https://doi.org/10.1080/13506129.2017.1324418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28494620/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Genetic%20testing%20improves%20identification%20of%20transthyretin%20amyloid%20(ATTR)%20subtype%20in%20cardiac%20amyloidosis&amp;author=EE%20Brown&amp;author=YZJ%20Lee&amp;author=MK%20Halushka&amp;author=C%20Steenbergen&amp;author=NM%20Johnson&amp;volume=24&amp;publication_year=2017&amp;pages=92-5&amp;pmid=28494620&amp;doi=10.1080/13506129.2017.1324418&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R43">
<span class="label">43.</span><cite>Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, Rezk T, Whelan C, Quarta C, Rowczenio D, et al. 
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J
2020;41:1439–47.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehz905" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31950987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Echocardiographic%20phenotype%20and%20prognosis%20in%20transthyretin%20cardiac%20amyloidosis&amp;author=L%20Chacko&amp;author=R%20Martone&amp;author=F%20Bandera&amp;author=T%20Lane&amp;author=A%20Martinez-Naharro&amp;volume=41&amp;publication_year=2020&amp;pages=1439-47&amp;pmid=31950987&amp;doi=10.1093/eurheartj/ehz905&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R44">
<span class="label">44.</span><cite>Czobor P, Hung YY, Baer D, McGlothlin D, Weisshaar D, Zaroff J. Amyloid cardiomyopathy in a large integrated health care system. Am Heart J
2019;216:42–52.</cite> [<a href="https://doi.org/10.1016/j.ahj.2019.06.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31401442/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J&amp;title=Amyloid%20cardiomyopathy%20in%20a%20large%20integrated%20health%20care%20system&amp;author=P%20Czobor&amp;author=YY%20Hung&amp;author=D%20Baer&amp;author=D%20McGlothlin&amp;author=D%20Weisshaar&amp;volume=216&amp;publication_year=2019&amp;pages=42-52&amp;pmid=31401442&amp;doi=10.1016/j.ahj.2019.06.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R45">
<span class="label">45.</span><cite>Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, Grogan M, Selby VN, Jacoby D, Hanna M, et al. 
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol
2019;74:285–95.</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.03.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30885685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Transthyretin%20Stabilization%20by%20AG10%20in%20Symptomatic%20Transthyretin%20Amyloid%20Cardiomyopathy&amp;author=DP%20Judge&amp;author=SB%20Heitner&amp;author=RH%20Falk&amp;author=MS%20Maurer&amp;author=SJ%20Shah&amp;volume=74&amp;publication_year=2019&amp;pages=285-95&amp;pmid=30885685&amp;doi=10.1016/j.jacc.2019.03.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R46">
<span class="label">46.</span><cite>Sperry BW, Vranian MN, Hachamovitch R, Joshi H, Ikram A, Phelan D, Hanna M. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis. J Am Heart Assoc
2016;5:e002877.</cite> [<a href="https://doi.org/10.1161/JAHA.115.002877" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4943263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27013539/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Heart%20Assoc&amp;title=Subtype-Specific%20Interactions%20and%20Prognosis%20in%20Cardiac%20Amyloidosis&amp;author=BW%20Sperry&amp;author=MN%20Vranian&amp;author=R%20Hachamovitch&amp;author=H%20Joshi&amp;author=A%20Ikram&amp;volume=5&amp;publication_year=2016&amp;pages=e002877&amp;pmid=27013539&amp;doi=10.1161/JAHA.115.002877&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R47">
<span class="label">47.</span><cite>Clemmensen TS, Molgaard H, Sorensen J, Eiskjaer H, Andersen NF, Mellemkjaer S, Andersen MJ, Tolbod LP, Harms HJ, Poulsen SH. Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis. Eur J Heart Fail
2017;19:1457–65.</cite> [<a href="https://doi.org/10.1002/ejhf.899" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28836315/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Inotropic%20myocardial%20reserve%20deficiency%20is%20the%20predominant%20feature%20of%20exercise%20haemodynamics%20in%20cardiac%20amyloidosis&amp;author=TS%20Clemmensen&amp;author=H%20Molgaard&amp;author=J%20Sorensen&amp;author=H%20Eiskjaer&amp;author=NF%20Andersen&amp;volume=19&amp;publication_year=2017&amp;pages=1457-65&amp;pmid=28836315&amp;doi=10.1002/ejhf.899&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R48">
<span class="label">48.</span><cite>He S, Tian Z, Guan H, Li J, Fang Q, Zhang S. Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy. Orphanet J Rare Dis
2019;14:251.</cite> [<a href="https://doi.org/10.1186/s13023-019-1235-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6852775/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31718691/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Orphanet%20J%20Rare%20Dis&amp;title=Clinical%20characteristics%20and%20prognosis%20of%20Chinese%20patients%20with%20hereditary%20transthyretin%20amyloid%20cardiomyopathy&amp;author=S%20He&amp;author=Z%20Tian&amp;author=H%20Guan&amp;author=J%20Li&amp;author=Q%20Fang&amp;volume=14&amp;publication_year=2019&amp;pages=251&amp;pmid=31718691&amp;doi=10.1186/s13023-019-1235-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R49">
<span class="label">49.</span><cite>Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, et al. 
Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol
2012;101:805–13.</cite> [<a href="https://doi.org/10.1007/s00392-012-0463-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3445797/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22584381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Res%20Cardiol&amp;title=Green%20tea%20halts%20progression%20of%20cardiac%20transthyretin%20amyloidosis:%20an%20observational%20report&amp;author=AV%20Kristen&amp;author=S%20Lehrke&amp;author=S%20Buss&amp;author=D%20Mereles&amp;author=H%20Steen&amp;volume=101&amp;publication_year=2012&amp;pages=805-13&amp;pmid=22584381&amp;doi=10.1007/s00392-012-0463-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R50">
<span class="label">50.</span><cite>Nakagawa M, Sekijima Y, Tojo K, Ikeda S. High prevalence of ATTR amyloidosis in endomyocardial biopsy-proven cardiac amyloidosis patients. Amyloid
2013;20:138–40.</cite> [<a href="https://doi.org/10.3109/13506129.2013.790809" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23638696/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=High%20prevalence%20of%20ATTR%20amyloidosis%20in%20endomyocardial%20biopsy-proven%20cardiac%20amyloidosis%20patients&amp;author=M%20Nakagawa&amp;author=Y%20Sekijima&amp;author=K%20Tojo&amp;author=S%20Ikeda&amp;volume=20&amp;publication_year=2013&amp;pages=138-40&amp;pmid=23638696&amp;doi=10.3109/13506129.2013.790809&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R51">
<span class="label">51.</span><cite>Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, et al. 
Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis. JACC Cardiovasc Imaging
2016;9:126–38.</cite> [<a href="https://doi.org/10.1016/j.jcmg.2015.05.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26777222/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Cardiovasc%20Imaging&amp;title=Causes%20and%20Consequences%20of%20Longitudinal%20LV%20Dysfunction%20Assessed%20by%202D%20Strain%20Echocardiography%20in%20Cardiac%20Amyloidosis&amp;author=J%20Ternacle&amp;author=D%20Bodez&amp;author=A%20Guellich&amp;author=E%20Audureau&amp;author=S%20Rappeneau&amp;volume=9&amp;publication_year=2016&amp;pages=126-38&amp;pmid=26777222&amp;doi=10.1016/j.jcmg.2015.05.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R52">
<span class="label">52.</span><cite>Adams D, Lozeron P, Theaudin M, Mincheva Z, Cauquil C, Adam C, Signate A, Vial C, Maisonobe T, Delmont E, et al. 
Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid
2012;19
Suppl 1:61–4.</cite> [<a href="https://doi.org/10.3109/13506129.2012.685665" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22620968/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Regional%20difference%20and%20similarity%20of%20familial%20amyloidosis%20with%20polyneuropathy%20in%20France&amp;author=D%20Adams&amp;author=P%20Lozeron&amp;author=M%20Theaudin&amp;author=Z%20Mincheva&amp;author=C%20Cauquil&amp;volume=19&amp;issue=Suppl%201&amp;publication_year=2012&amp;pages=61-4&amp;pmid=22620968&amp;doi=10.3109/13506129.2012.685665&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R53">
<span class="label">53.</span><cite>Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, et al. 
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med
2018;379:22–31.</cite> [<a href="https://doi.org/10.1056/NEJMoa1716793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12611561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Inotersen%20Treatment%20for%20Patients%20with%20Hereditary%20Transthyretin%20Amyloidosis&amp;author=MD%20Benson&amp;author=M%20Waddington-Cruz&amp;author=JL%20Berk&amp;author=M%20Polydefkis&amp;author=PJ%20Dyck&amp;volume=379&amp;publication_year=2018&amp;pages=22-31&amp;pmid=29972757&amp;doi=10.1056/NEJMoa1716793&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R54">
<span class="label">54.</span><cite>Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, et al. 
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol
2016;263:916–24.</cite> [<a href="https://doi.org/10.1007/s00415-016-8064-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26984605/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurol&amp;title=Monitoring%20effectiveness%20and%20safety%20of%20Tafamidis%20in%20transthyretin%20amyloidosis%20in%20Italy:%20a%20longitudinal%20multicenter%20study%20in%20a%20non-endemic%20area&amp;author=A%20Cortese&amp;author=G%20Vita&amp;author=M%20Luigetti&amp;author=M%20Russo&amp;author=G%20Bisogni&amp;volume=263&amp;publication_year=2016&amp;pages=916-24&amp;pmid=26984605&amp;doi=10.1007/s00415-016-8064-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R55">
<span class="label">55.</span><cite>Delahaye N, Rouzet F, Sarda L, Tamas C, Dinanian S, Plante-Bordeneuve V, Adams D, Samuel D, Merlet P, Syrota A, et al. 
Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore)
2006;85:229–38.</cite> [<a href="https://doi.org/10.1097/01.md.0000232559.22098.c3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16862048/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medicine%20(Baltimore)&amp;title=Impact%20of%20liver%20transplantation%20on%20cardiac%20autonomic%20denervation%20in%20familial%20amyloid%20polyneuropathy&amp;author=N%20Delahaye&amp;author=F%20Rouzet&amp;author=L%20Sarda&amp;author=C%20Tamas&amp;author=S%20Dinanian&amp;volume=85&amp;publication_year=2006&amp;pages=229-38&amp;pmid=16862048&amp;doi=10.1097/01.md.0000232559.22098.c3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R56">
<span class="label">56.</span><cite>Lavigne-Moreira C, Marques VD, Goncalves MVM, de Oliveira MF, Tomaselli PJ, Nunez JC, do Nascimento OJM, Barreira AA, Marques W Jr.
The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population. J Peripher Nerv Syst
2018;23:134–7.</cite> [<a href="https://doi.org/10.1111/jns.12259" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29520877/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Peripher%20Nerv%20Syst&amp;title=The%20genetic%20heterogeneity%20of%20hereditary%20transthyretin%20amyloidosis%20in%20a%20sample%20of%20the%20Brazilian%20population&amp;author=C%20Lavigne-Moreira&amp;author=VD%20Marques&amp;author=MVM%20Goncalves&amp;author=MF%20de%20Oliveira&amp;author=PJ%20Tomaselli&amp;volume=23&amp;publication_year=2018&amp;pages=134-7&amp;pmid=29520877&amp;doi=10.1111/jns.12259&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R57">
<span class="label">57.</span><cite>Leibou L, Frand J, Sadeh M, Lossos A, Kremer E, Livneh A, Yarnitsky D, Herman O, Dabby R. Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy. Isr Med Assoc J
2012;14:662–5.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/23240369/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Isr%20Med%20Assoc%20J&amp;title=Clinical%20and%20genetic%20findings%20in%20eight%20Israeli%20patients%20with%20transthyretin-associated%20familial%20amyloid%20polyneuropathy&amp;author=L%20Leibou&amp;author=J%20Frand&amp;author=M%20Sadeh&amp;author=A%20Lossos&amp;author=E%20Kremer&amp;volume=14&amp;publication_year=2012&amp;pages=662-5&amp;pmid=23240369&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R58">
<span class="label">58.</span><cite>Luigetti M, Conte A, Del Grande A, Bisogni G, Madia F, Lo Monaco M, Laurenti L, Obici L, Merlini G, Sabatelli M. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2013;34:1057–63.</cite> [<a href="https://doi.org/10.1007/s10072-012-1105-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22592564/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurological%20sciences%20:%20official%20journal%20of%20the%20Italian%20Neurological%20Society%20and%20of%20the%20Italian%20Society%20of%20Clinical%20Neurophysiology&amp;title=TTR-related%20amyloid%20neuropathy:%20clinical,%20electrophysiological%20and%20pathological%20findings%20in%2015%20unrelated%20patients&amp;author=M%20Luigetti&amp;author=A%20Conte&amp;author=A%20Del%20Grande&amp;author=G%20Bisogni&amp;author=F%20Madia&amp;volume=34&amp;publication_year=2013&amp;pages=1057-63&amp;pmid=22592564&amp;doi=10.1007/s10072-012-1105-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R59">
<span class="label">59.</span><cite>Okamoto S, Zhao Y, Lindqvist P, Backman C, Ericzon BG, Wijayatunga P, Henein MY, Suhr OB. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid
2011;18:200–5.</cite> [<a href="https://doi.org/10.3109/13506129.2011.615872" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22080763/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Development%20of%20cardiomyopathy%20after%20liver%20transplantation%20in%20Swedish%20hereditary%20transthyretin%20amyloidosis%20(ATTR)%20patients&amp;author=S%20Okamoto&amp;author=Y%20Zhao&amp;author=P%20Lindqvist&amp;author=C%20Backman&amp;author=BG%20Ericzon&amp;volume=18&amp;publication_year=2011&amp;pages=200-5&amp;pmid=22080763&amp;doi=10.3109/13506129.2011.615872&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R60">
<span class="label">60.</span><cite>Suhr OB, Larsson M, Ericzon BG, Wilczek HE, investigators FAs. Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry. Transplantation
2016;100:373–81.</cite> [<a href="https://doi.org/10.1097/TP.0000000000001021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4732012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26656838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transplantation&amp;title=Survival%20After%20Transplantation%20in%20Patients%20With%20Mutations%20Other%20Than%20Val30Met:%20Extracts%20From%20the%20FAP%20World%20Transplant%20Registry&amp;author=OB%20Suhr&amp;author=M%20Larsson&amp;author=BG%20Ericzon&amp;author=HE%20Wilczek&amp;volume=100&amp;publication_year=2016&amp;pages=373-81&amp;pmid=26656838&amp;doi=10.1097/TP.0000000000001021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R61">
<span class="label">61.</span><cite>Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, et al. 
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med
2018;379:11–21.</cite> [<a href="https://doi.org/10.1056/NEJMoa1716153" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29972753/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Patisiran,%20an%20RNAi%20Therapeutic,%20for%20Hereditary%20Transthyretin%20Amyloidosis&amp;author=D%20Adams&amp;author=A%20Gonzalez-Duarte&amp;author=WD%20O%E2%80%99Riordan&amp;author=CC%20Yang&amp;author=M%20Ueda&amp;volume=379&amp;publication_year=2018&amp;pages=11-21&amp;pmid=29972753&amp;doi=10.1056/NEJMoa1716153&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R62">
<span class="label">62.</span><cite>Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J, Powell C, Karsten V, Vest J, Maurer MS. DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid
2020:1–8.</cite> [<a href="https://doi.org/10.1080/13506129.2020.1764928" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32456532/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=DISCOVERY:%20prevalence%20of%20transthyretin%20(TTR)%20mutations%20in%20a%20US-centric%20patient%20population%20suspected%20of%20having%20cardiac%20amyloidosis&amp;author=O%20Akinboboye&amp;author=K%20Shah&amp;author=AL%20Warner&amp;author=T%20Damy&amp;author=HA%20Taylor&amp;publication_year=2020&amp;pages=1-8&amp;pmid=32456532&amp;doi=10.1080/13506129.2020.1764928&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R63">
<span class="label">63.</span><cite>Arvanitis M, Chan GG, Jacobson DR, Berk JL, Connors LH, Ruberg FL. Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid
2017;24:253–5.</cite> [<a href="https://doi.org/10.1080/13506129.2017.1391086" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5894279/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29052438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Prevalence%20of%20mutant%20ATTR%20cardiac%20amyloidosis%20in%20elderly%20African%20Americans%20with%20heart%20failure&amp;author=M%20Arvanitis&amp;author=GG%20Chan&amp;author=DR%20Jacobson&amp;author=JL%20Berk&amp;author=LH%20Connors&amp;volume=24&amp;publication_year=2017&amp;pages=253-5&amp;pmid=29052438&amp;doi=10.1080/13506129.2017.1391086&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R64">
<span class="label">64.</span><cite>Reddi HV, Jenkins S, Theis J, Thomas BC, Connors LH, Van Rhee F, Highsmith WE, Jr. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life. J Mol Diagn
2014;16:68–74.</cite> [<a href="https://doi.org/10.1016/j.jmoldx.2013.08.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24184229/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Diagn&amp;title=Jr.%20Homozygosity%20for%20the%20V122I%20mutation%20in%20transthyretin%20is%20associated%20with%20earlier%20onset%20of%20cardiac%20amyloidosis%20in%20the%20African%20American%20population%20in%20the%20seventh%20decade%20of%20life&amp;author=HV%20Reddi&amp;author=S%20Jenkins&amp;author=J%20Theis&amp;author=BC%20Thomas&amp;author=LH%20Connors&amp;volume=16&amp;publication_year=2014&amp;pages=68-74&amp;pmid=24184229&amp;doi=10.1016/j.jmoldx.2013.08.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R65">
<span class="label">65.</span><cite>Buxbaum J, Jacobson DR, Tagoe C, Alexander A, Kitzman DW, Greenberg B, Thaneemit-Chen S, Lavori P. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol
2006;47:1724–5.</cite> [<a href="https://doi.org/10.1016/j.jacc.2006.01.042" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16631014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Transthyretin%20V122I%20in%20African%20Americans%20with%20congestive%20heart%20failure&amp;author=J%20Buxbaum&amp;author=DR%20Jacobson&amp;author=C%20Tagoe&amp;author=A%20Alexander&amp;author=DW%20Kitzman&amp;volume=47&amp;publication_year=2006&amp;pages=1724-5&amp;pmid=16631014&amp;doi=10.1016/j.jacc.2006.01.042&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R66">
<span class="label">66.</span><cite>Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health
2013;9:229–35.</cite> [<a href="https://doi.org/10.2217/ahe.13.10" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3780445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24073013/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aging%20Health&amp;title=Comparison%20of%20cardiac%20amyloidosis%20due%20to%20wild-type%20and%20V122I%20transthyretin%20in%20older%20adults%20referred%20to%20an%20academic%20medical%20center&amp;author=RC%20Givens&amp;author=C%20Russo&amp;author=P%20Green&amp;author=MS%20Maurer&amp;volume=9&amp;publication_year=2013&amp;pages=229-35&amp;pmid=24073013&amp;doi=10.2217/ahe.13.10&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R67">
<span class="label">67.</span><cite>Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail
2015;8:519–26.</cite> [<a href="https://doi.org/10.1161/CIRCHEARTFAILURE.113.000890" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25872787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20Heart%20Fail&amp;title=Tafamidis%20in%20transthyretin%20amyloid%20cardiomyopathy:%20effects%20on%20transthyretin%20stabilization%20and%20clinical%20outcomes&amp;author=MS%20Maurer&amp;author=DR%20Grogan&amp;author=DP%20Judge&amp;author=R%20Mundayat&amp;author=J%20Packman&amp;volume=8&amp;publication_year=2015&amp;pages=519-26&amp;pmid=25872787&amp;doi=10.1161/CIRCHEARTFAILURE.113.000890&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R68">
<span class="label">68.</span><cite>Monfort A, Banydeen R, Demoniere F, Courty B, Codiat R, Neviere R, Inamo J. Restrictive cardiac phenotype as primary cause of impaired aerobic capacity in Afro-Caribbean patients with val122ile variant transthyretin amyloid cardiomyopathy. Amyloid
2020;27:145–52.</cite> [<a href="https://doi.org/10.1080/13506129.2020.1722098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32024385/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Restrictive%20cardiac%20phenotype%20as%20primary%20cause%20of%20impaired%20aerobic%20capacity%20in%20Afro-Caribbean%20patients%20with%20val122ile%20variant%20transthyretin%20amyloid%20cardiomyopathy&amp;author=A%20Monfort&amp;author=R%20Banydeen&amp;author=F%20Demoniere&amp;author=B%20Courty&amp;author=R%20Codiat&amp;volume=27&amp;publication_year=2020&amp;pages=145-52&amp;pmid=32024385&amp;doi=10.1080/13506129.2020.1722098&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R69">
<span class="label">69.</span><cite>Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, et al. 
Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J
2012;164:222–8 e1.</cite> [<a href="https://doi.org/10.1016/j.ahj.2012.04.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22877808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J&amp;title=Prospective%20evaluation%20of%20the%20morbidity%20and%20mortality%20of%20wild-type%20and%20V122I%20mutant%20transthyretin%20amyloid%20cardiomyopathy:%20the%20Transthyretin%20Amyloidosis%20Cardiac%20Study%20(TRACS)&amp;author=FL%20Ruberg&amp;author=MS%20Maurer&amp;author=DP%20Judge&amp;author=S%20Zeldenrust&amp;author=M%20Skinner&amp;volume=164&amp;publication_year=2012&amp;pages=222-8&amp;pmid=22877808&amp;doi=10.1016/j.ahj.2012.04.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R70">
<span class="label">70.</span><cite>Singh A, Geller HI, Falk RH. Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis. J Am Coll Cardiol
2017;69:757–8.</cite> [<a href="https://doi.org/10.1016/j.jacc.2016.09.987" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28183520/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Val122Ile%20mt-ATTR%20Has%20a%20Worse%20Survival%20Than%20wt-ATTR%20Cardiac%20Amyloidosis&amp;author=A%20Singh&amp;author=HI%20Geller&amp;author=RH%20Falk&amp;volume=69&amp;publication_year=2017&amp;pages=757-8&amp;pmid=28183520&amp;doi=10.1016/j.jacc.2016.09.987&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R71">
<span class="label">71.</span><cite>Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, et al. 
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation
2019;140:16–26.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.118.038169" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31109193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Natural%20History,%20Quality%20of%20Life,%20and%20Outcome%20in%20Cardiac%20Transthyretin%20Amyloidosis&amp;author=T%20Lane&amp;author=M%20Fontana&amp;author=A%20Martinez-Naharro&amp;author=CC%20Quarta&amp;author=CJ%20Whelan&amp;volume=140&amp;publication_year=2019&amp;pages=16-26&amp;pmid=31109193&amp;doi=10.1161/CIRCULATIONAHA.118.038169&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R72">
<span class="label">72.</span><cite>Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant
2005;24:1763–5.</cite> [<a href="https://doi.org/10.1016/j.healun.2004.08.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16297778/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Heart%20Lung%20Transplant&amp;title=Outcome%20of%20heart%20transplantation%20in%20patients%20with%20amyloid%20cardiomyopathy&amp;author=J%20Kpodonu&amp;author=MG%20Massad&amp;author=A%20Caines&amp;author=AS%20Geha&amp;volume=24&amp;publication_year=2005&amp;pages=1763-5&amp;pmid=16297778&amp;doi=10.1016/j.healun.2004.08.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R73">
<span class="label">73.</span><cite>Barrett CD, Alexander KM, Zhao H, Haddad F, Cheng P, Liao R, Wheeler MT, Liedtke M, Schrier S, Arai S, et al. 
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC Heart Fail
2020;8:461–8.</cite> [<a href="https://doi.org/10.1016/j.jchf.2019.12.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32387068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Heart%20Fail&amp;title=Outcomes%20in%20Patients%20With%20Cardiac%20Amyloidosis%20Undergoing%20Heart%20Transplantation&amp;author=CD%20Barrett&amp;author=KM%20Alexander&amp;author=H%20Zhao&amp;author=F%20Haddad&amp;author=P%20Cheng&amp;volume=8&amp;publication_year=2020&amp;pages=461-8&amp;pmid=32387068&amp;doi=10.1016/j.jchf.2019.12.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R74">
<span class="label">74.</span><cite>Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, et al. 
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation
2020;141:e139–e596.</cite> [<a href="https://doi.org/10.1161/CIR.0000000000000757" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31992061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Heart%20Disease%20and%20Stroke%20Statistics%E2%80%942020%20Update:%20A%20Report%20From%20the%20American%20Heart%20Association&amp;author=SS%20Virani&amp;author=A%20Alonso&amp;author=EJ%20Benjamin&amp;author=MS%20Bittencourt&amp;author=CW%20Callaway&amp;volume=141&amp;publication_year=2020&amp;pages=e139-e596&amp;pmid=31992061&amp;doi=10.1161/CIR.0000000000000757&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R75">
<span class="label">75.</span><cite>Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, Burke GL, Lima JA. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med
2008;168:2138–45.</cite> [<a href="https://doi.org/10.1001/archinte.168.19.2138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3038918/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955644/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Intern%20Med&amp;title=Differences%20in%20the%20incidence%20of%20congestive%20heart%20failure%20by%20ethnicity:%20the%20multi-ethnic%20study%20of%20atherosclerosis&amp;author=H%20Bahrami&amp;author=R%20Kronmal&amp;author=DA%20Bluemke&amp;author=J%20Olson&amp;author=S%20Shea&amp;volume=168&amp;publication_year=2008&amp;pages=2138-45&amp;pmid=18955644&amp;doi=10.1001/archinte.168.19.2138&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R76">
<span class="label">76.</span><cite>Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, Psaty BM, Smith NL, Newman AB, Rodondi N, Satterfield S, Bauer DC, Bibbins-Domingo K, et al. 
Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. Arch Intern Med
2009;169:708–15.</cite> [<a href="https://doi.org/10.1001/archinternmed.2009.40" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2756793/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19365001/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Intern%20Med&amp;title=Epidemiology%20of%20incident%20heart%20failure%20in%20a%20contemporary%20elderly%20cohort:%20the%20health,%20aging,%20and%20body%20composition%20study&amp;author=A%20Kalogeropoulos&amp;author=V%20Georgiopoulou&amp;author=SB%20Kritchevsky&amp;author=BM%20Psaty&amp;author=NL%20Smith&amp;volume=169&amp;publication_year=2009&amp;pages=708-15&amp;pmid=19365001&amp;doi=10.1001/archinternmed.2009.40&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R77">
<span class="label">77.</span><cite>Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol
2008;101:1016–22.</cite> [<a href="https://doi.org/10.1016/j.amjcard.2007.11.061" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18359324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&amp;title=Heart%20failure%20incidence%20and%20survival%20(from%20the%20Atherosclerosis%20Risk%20in%20Communities%20study)&amp;author=LR%20Loehr&amp;author=WD%20Rosamond&amp;author=PP%20Chang&amp;author=AR%20Folsom&amp;author=LE%20Chambless&amp;volume=101&amp;publication_year=2008&amp;pages=1016-22&amp;pmid=18359324&amp;doi=10.1016/j.amjcard.2007.11.061&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R78">
<span class="label">78.</span><cite>Chang PP, Chambless LE, Shahar E, Bertoni AG, Russell SD, Ni H, He M, Mosley TH, Wagenknecht LE, Samdarshi TE, et al. 
Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). Am J Cardiol
2014;113:504–10.</cite> [<a href="https://doi.org/10.1016/j.amjcard.2013.10.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4038413/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24342763/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiol&amp;title=Incidence%20and%20survival%20of%20hospitalized%20acute%20decompensated%20heart%20failure%20in%20four%20US%20communities%20(from%20the%20Atherosclerosis%20Risk%20in%20Communities%20Study)&amp;author=PP%20Chang&amp;author=LE%20Chambless&amp;author=E%20Shahar&amp;author=AG%20Bertoni&amp;author=SD%20Russell&amp;volume=113&amp;publication_year=2014&amp;pages=504-10&amp;pmid=24342763&amp;doi=10.1016/j.amjcard.2013.10.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R79">
<span class="label">79.</span><cite>Micheletti SJ, Bryc K, Ancona Esselmann SG, Freyman WA, Moreno ME, Poznik GD, Shastri AJ, andMe Research T, Beleza S, Mountain JL. Genetic Consequences of the Transatlantic Slave Trade in the Americas. Am J Hum Genet
2020;107:265–77.</cite> [<a href="https://doi.org/10.1016/j.ajhg.2020.06.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7413858/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32707084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Hum%20Genet&amp;title=Genetic%20Consequences%20of%20the%20Transatlantic%20Slave%20Trade%20in%20the%20Americas&amp;author=SJ%20Micheletti&amp;author=K%20Bryc&amp;author=SG%20Ancona%20Esselmann&amp;author=WA%20Freyman&amp;author=ME%20Moreno&amp;volume=107&amp;publication_year=2020&amp;pages=265-77&amp;pmid=32707084&amp;doi=10.1016/j.ajhg.2020.06.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R80">
<span class="label">80.</span><cite>Sher T, Velarde GP, Gertz MA. V122I Transthyretin Cardiomyopathy: An Opportunity to Build Trust and Resolve Disparities. J Am Coll Cardiol
2020;76:93–5.</cite> [<a href="https://doi.org/10.1016/j.jacc.2020.04.074" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32616166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=V122I%20Transthyretin%20Cardiomyopathy:%20An%20Opportunity%20to%20Build%20Trust%20and%20Resolve%20Disparities&amp;author=T%20Sher&amp;author=GP%20Velarde&amp;author=MA%20Gertz&amp;volume=76&amp;publication_year=2020&amp;pages=93-5&amp;pmid=32616166&amp;doi=10.1016/j.jacc.2020.04.074&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R81">
<span class="label">81.</span><cite>Soares ML, Coelho T, Sousa A, Batalov S, Conceição I, Sales-Luís ML, Ritchie MD, Williams SM, Nievergelt CM, Schork NJ, et al. 
Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease. Hum Mol Genet
2005;14:543–53.</cite> [<a href="https://doi.org/10.1093/hmg/ddi051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15649951/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hum%20Mol%20Genet&amp;title=Susceptibility%20and%20modifier%20genes%20in%20Portuguese%20transthyretin%20V30M%20amyloid%20polyneuropathy:%20complexity%20in%20a%20single-gene%20disease&amp;author=ML%20Soares&amp;author=T%20Coelho&amp;author=A%20Sousa&amp;author=S%20Batalov&amp;author=I%20Concei%C3%A7%C3%A3o&amp;volume=14&amp;publication_year=2005&amp;pages=543-53&amp;pmid=15649951&amp;doi=10.1093/hmg/ddi051&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R82">
<span class="label">82.</span><cite>Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, Nylander PO, Teixeira A, Saraiva MJ, Costa PP. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet
1994;31:351–4.</cite> [<a href="https://doi.org/10.1136/jmg.31.5.351" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1049863/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8064809/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Genet&amp;title=Geographical%20distribution%20of%20TTR%20met30%20carriers%20in%20northern%20Sweden:%20discrepancy%20between%20carrier%20frequency%20and%20prevalence%20rate&amp;author=G%20Holmgren&amp;author=PM%20Costa&amp;author=C%20Andersson&amp;author=K%20Asplund&amp;author=L%20Steen&amp;volume=31&amp;publication_year=1994&amp;pages=351-4&amp;pmid=8064809&amp;doi=10.1136/jmg.31.5.351&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R83">
<span class="label">83.</span><cite>Suther S, Kiros GE. Barriers to the use of genetic testing: a study of racial and ethnic disparities. Genet Med
2009;11:655–62.</cite> [<a href="https://doi.org/10.1097/GIM.0b013e3181ab22aa" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19752639/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genet%20Med&amp;title=Barriers%20to%20the%20use%20of%20genetic%20testing:%20a%20study%20of%20racial%20and%20ethnic%20disparities&amp;author=S%20Suther&amp;author=GE%20Kiros&amp;volume=11&amp;publication_year=2009&amp;pages=655-62&amp;pmid=19752639&amp;doi=10.1097/GIM.0b013e3181ab22aa&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R84">
<span class="label">84.</span><cite>Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. Cell
2019;177:26–31.</cite> [<a href="https://doi.org/10.1016/j.cell.2019.02.048" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7380073/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30901543/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=The%20Missing%20Diversity%20in%20Human%20Genetic%20Studies&amp;author=G%20Sirugo&amp;author=SM%20Williams&amp;author=SA%20Tishkoff&amp;volume=177&amp;publication_year=2019&amp;pages=26-31&amp;pmid=30901543&amp;doi=10.1016/j.cell.2019.02.048&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R85">
<span class="label">85.</span><cite>Muller C, Lee SM, Barge W, Siddique SM, Berera S, Wideroff G, Tondon R, Chang J, Peterson M, Stoll J, et al. 
Low Referral Rate for Genetic Testing in Racially and Ethnically Diverse Patients Despite Universal Colorectal Cancer Screening. Clin Gastroenterol Hepatol
2018;16:1911–8 e2.</cite> [<a href="https://doi.org/10.1016/j.cgh.2018.08.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6866232/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30130624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=Low%20Referral%20Rate%20for%20Genetic%20Testing%20in%20Racially%20and%20Ethnically%20Diverse%20Patients%20Despite%20Universal%20Colorectal%20Cancer%20Screening&amp;author=C%20Muller&amp;author=SM%20Lee&amp;author=W%20Barge&amp;author=SM%20Siddique&amp;author=S%20Berera&amp;volume=16&amp;publication_year=2018&amp;pages=1911-8%20e2&amp;pmid=30130624&amp;doi=10.1016/j.cgh.2018.08.038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R86">
<span class="label">86.</span><cite>Capers Q, Sharalaya Z. Racial Disparities in Cardiovascular Care: A Review of Culprits and Potential Solutions. Journal of Racial and Ethnic Health Disparities
2014;1:171–80.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Racial%20and%20Ethnic%20Health%20Disparities&amp;title=Racial%20Disparities%20in%20Cardiovascular%20Care:%20A%20Review%20of%20Culprits%20and%20Potential%20Solutions&amp;author=Q%20Capers&amp;author=Z%20Sharalaya&amp;volume=1&amp;publication_year=2014&amp;pages=171-80&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R87">
<span class="label">87.</span><cite>Drazner MH. Left ventricular hypertrophy is more common in black than white hypertensives: is this news? Hypertension
2004;43:1160–1.</cite> [<a href="https://doi.org/10.1161/01.HYP.0000128740.68851.8a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15123569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hypertension&amp;title=Left%20ventricular%20hypertrophy%20is%20more%20common%20in%20black%20than%20white%20hypertensives:%20is%20this%20news&amp;author=MH%20Drazner&amp;volume=43&amp;publication_year=2004&amp;pages=1160-1&amp;pmid=15123569&amp;doi=10.1161/01.HYP.0000128740.68851.8a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R88">
<span class="label">88.</span><cite>Maurer M, National Heart L, Institute B, Center BM, Center HH, Institute TSR, University C. Screening for Cardiac Amyloidosis Using Nuclear Imaging for Minority Populations. <a href="https://ClinicalTrials.gov/show/NCT03812172;2019" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://ClinicalTrials.gov/show/NCT03812172;2019</a>.</cite>
</li>
<li id="R89">
<span class="label">89.</span><cite>Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, et al. 
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail
2020;0.</cite> [<a href="https://doi.org/10.1016/j.jchf.2020.09.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33309574/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Heart%20Fail&amp;title=Efficacy%20of%20Tafamidis%20in%20Patients%20With%20Hereditary%20and%20Wild-Type%20Transthyretin%20Amyloid%20Cardiomyopathy:%20Further%20Analyses%20From%20ATTR-ACT&amp;author=C%20Rapezzi&amp;author=P%20Elliott&amp;author=T%20Damy&amp;author=J%20Nativi-Nicolau&amp;author=JL%20Berk&amp;publication_year=2020&amp;pages=0&amp;pmid=33309574&amp;doi=10.1016/j.jchf.2020.09.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R90">
<span class="label">90.</span><cite>Gagliardi C, Perfetto F, Lorenzini M, Ferlini A, Salvi F, Milandri A, Quarta CC, Taborchi G, Bartolini S, Frusconi S, et al. 
Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. 2018;20:1417–25.</cite> [<a href="https://doi.org/10.1002/ejhf.1285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30070416/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Phenotypic%20profile%20of%20Ile68Leu%20transthyretin%20amyloidosis:%20an%20underdiagnosed%20cause%20of%20heart%20failure&amp;author=C%20Gagliardi&amp;author=F%20Perfetto&amp;author=M%20Lorenzini&amp;author=A%20Ferlini&amp;author=F%20Salvi&amp;volume=20&amp;publication_year=2018&amp;pages=1417-25&amp;pmid=30070416&amp;doi=10.1002/ejhf.1285&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R91">
<span class="label">91.</span><cite>Batra J, Rosenblum H, Defilippis EM, Griffin JM, Saith SE, Gamino D, Teruya S, Santos JL, Helmke S, Burkhoff D, et al. 
Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressure-Volume Analysis. J Card Fail
2020.</cite> [<a href="https://doi.org/10.1016/j.cardfail.2020.08.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7869136/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32829019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Card%20Fail&amp;title=Sex%20Differences%20in%20the%20Phenotype%20of%20Transthyretin%20Cardiac%20Amyloidosis%20Due%20to%20Val122Ile%20Mutation:%20Insights%20from%20Noninvasive%20Pressure-Volume%20Analysis&amp;author=J%20Batra&amp;author=H%20Rosenblum&amp;author=EM%20Defilippis&amp;author=JM%20Griffin&amp;author=SE%20Saith&amp;publication_year=2020&amp;pmid=32829019&amp;doi=10.1016/j.cardfail.2020.08.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R92">
<span class="label">92.</span><cite>Goncalves I, Alves CH, Quintela T, Baltazar G, Socorro S, Saraiva MJ, Abreu R, Santos CR. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem
2008;317:137–42.</cite> [<a href="https://doi.org/10.1007/s11010-008-9841-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18568387/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Cell%20Biochem&amp;title=Transthyretin%20is%20up-regulated%20by%20sex%20hormones%20in%20mice%20liver&amp;author=I%20Goncalves&amp;author=CH%20Alves&amp;author=T%20Quintela&amp;author=G%20Baltazar&amp;author=S%20Socorro&amp;volume=317&amp;publication_year=2008&amp;pages=137-42&amp;pmid=18568387&amp;doi=10.1007/s11010-008-9841-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R93">
<span class="label">93.</span><cite>Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F, Longhi S, Ciliberti P, Pastorelli F, Biagini E, Leone O, et al. 
Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid
2008;15:40–8.</cite> [<a href="https://doi.org/10.1080/13506120701815373" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18266120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Amyloid&amp;title=Gender-related%20risk%20of%20myocardial%20involvement%20in%20systemic%20amyloidosis&amp;author=C%20Rapezzi&amp;author=L%20Riva&amp;author=CC%20Quarta&amp;author=E%20Perugini&amp;author=F%20Salvi&amp;volume=15&amp;publication_year=2008&amp;pages=40-8&amp;pmid=18266120&amp;doi=10.1080/13506120701815373&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R94">
<span class="label">94.</span><cite>Bruno M, Castano A, Burton A, Grodin JL. Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. Heart Fail Rev
2021;26:35–45.</cite> [<a href="https://doi.org/10.1007/s10741-020-10010-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7769788/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32794090/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart%20Fail%20Rev&amp;title=Transthyretin%20amyloid%20cardiomyopathy%20in%20women:%20frequency,%20characteristics,%20and%20diagnostic%20challenges&amp;author=M%20Bruno&amp;author=A%20Castano&amp;author=A%20Burton&amp;author=JL%20Grodin&amp;volume=26&amp;publication_year=2021&amp;pages=35-45&amp;pmid=32794090&amp;doi=10.1007/s10741-020-10010-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R95">
<span class="label">95.</span><cite>Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation
2011;124:2145–54.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.110.968792" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3362050/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22064958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Sex/gender%20differences%20in%20cardiovascular%20disease%20prevention:%20what%20a%20difference%20a%20decade%20makes&amp;author=L%20Mosca&amp;author=E%20Barrett-Connor&amp;author=NK%20Wenger&amp;volume=124&amp;publication_year=2011&amp;pages=2145-54&amp;pmid=22064958&amp;doi=10.1161/CIRCULATIONAHA.110.968792&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R96">
<span class="label">96.</span><cite>Williams RA. Cardiovascular disease in African American women: a health care disparities issue. J Natl Med Assoc
2009;101:536–40.</cite> [<a href="https://doi.org/10.1016/s0027-9684(15)30938-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19585921/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Med%20Assoc&amp;title=Cardiovascular%20disease%20in%20African%20American%20women:%20a%20health%20care%20disparities%20issue&amp;author=RA%20Williams&amp;volume=101&amp;publication_year=2009&amp;pages=536-40&amp;pmid=19585921&amp;doi=10.1016/s0027-9684(15)30938-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R97">
<span class="label">97.</span><cite>Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. Ther Clin Risk Manag
2020;16:109–23.</cite> [<a href="https://doi.org/10.2147/TCRM.S219979" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7041433/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32110029/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther%20Clin%20Risk%20Manag&amp;title=Diagnosis%20and%20Treatment%20of%20Hereditary%20Transthyretin%20Amyloidosis%20(hATTR)%20Polyneuropathy:%20Current%20Perspectives%20on%20Improving%20Patient%20Care&amp;author=M%20Luigetti&amp;author=A%20Romano&amp;author=A%20Di%20Paolantonio&amp;author=G%20Bisogni&amp;author=M%20Sabatelli&amp;volume=16&amp;publication_year=2020&amp;pages=109-23&amp;pmid=32110029&amp;doi=10.2147/TCRM.S219979&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>003356 - Supplemental Material</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/8530896/bin/NIHMS1731320-supplement-003356_-_Supplemental_Material.pdf" data-ga-action="click_feat_suppl" class="usa-link">NIHMS1731320-supplement-003356_-_Supplemental_Material.pdf</a><sup> (700.8KB, pdf) </sup>
</div></div></section></section></section></section></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1161/CIRCGEN.121.003356"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/nihms-1731320.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (991.3 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/8530896/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/8530896/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC8530896%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC8530896/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC8530896/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC8530896/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/34461737/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC8530896/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/34461737/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC8530896/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/8530896/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="WVQQ6P20ARPc2q5tRfCJ8GpqtQvwzDwUXEDxzAqcxd4ImToO5tHpWkR0eEL6cddy">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
